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Overall cancer survival rates steadily decline each year following diagnosis and side effects of
chemotherapy restrict its use. The chemotherapeutic cis-diamminedichloro-platinum (cisplatin,
CDDP) is poorly soluble and has dose limiting side effects. Nanoparticle delivery systems can
deliver a higher dose of drug directly to the tumor by both active and passive targeting, holding
promise of fewer side effects and greater anti-tumor efficacy. To date, few nanoparticle systems
have been FDA approved for the treatment of cancer due to complicated physicochemical
characterization, drug inactivation by the delivery system, scale-up challenges, and lack of
demonstrated in vivo safety and efficacy. Further research is needed in this area.
This dissertation examined a naturally biocompatible carrier for delivery of CDDP:
calcium phosphate (CaP). Three molecules were tested to stabilize CaP nanoparticles (nCaP) and
increase injectability: sodium polyacrylate (D), sodium citrate (CIT) and carboxymethyl
hyaluronic acid (CMHA). nCaPDCDDP and nCaPCITCDDP were examined against a head &
neck cancer (HNC) model, because HNC patients could greatly benefit from localized
chemotherapy prior to surgical resection. Triple negative breast cancer (TNBC) with a
CD44high/CD24-/low

cell

phenotype

has

emerged

as

an

important

new

target

for

chemotherapeutics. CD44 is the major receptor for hyaluronic acid, targetable with CMHA.
These studies showed all three molecules stabilized nCaP as measured by light scattering, zeta
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potential, x-ray diffraction and transmission electron microscopy, and released biologically
active CDDP as measured by in vitro release studies and in vitro cytotoxicity testing. However,
intratumoral (IT) delivery of nCaPDCDDP or nCaPCITCDDP was not as effective as CDDP IT in
vivo against murine and human HNC tumor models, due stabilizer inhibition of CDDP. Surface
plasmon resonance proved CMHA and nCaPCMHACDDP bind CD44. CMHA didn’t inactivate
CDDP and nCaPCMHACDDP had comparable activity to free CDDP in vitro. Local delivery of
nCaPCMHACDDP did not demonstrate a benefit over local delivery of CDDP in a human TBNC
mouse model, due to lack of even distribution of nanoparticles throughout the tumor where
CDDP alone could freely diffuse. These studies show that localized delivery of CDDP remains a
promising strategy to increase drug effectiveness while decreasing drug side-effects that
negatively impact cancer patients.
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Chapter 1
Specific Aims and Background

1.1 Specific Aims
Despite a combination of surgery, radiation and/or chemotherapy overall survival rates for a
majority of cancers steadily decline each year following diagnosis, with an estimated 1,600
deaths per day in 20131,2. Chemotherapy has many debilitating side effects because it kills
normal replicating cells while killing cancer cells. Nanoparticles can deliver a higher dose of
drug directly to the tumor by both active and passive targeting, with the goal of fewer side effects
and greater anti-tumor efficacy3–5. However, few nanoparticle systems have been FDA approved
for the treatment of cancer due to complicated physicochemical characterization, scale-up
challenges6, and lack of demonstrated in vivo safety and efficacy7. Stabilizer molecules are often
needed to prevent nanoparticle aggregation but may negatively interact with the drug8–10.
Targeting ligands that may increase specific cancer cell interaction must be carefully attached to
present the active groups to the cells11–13. In order to develop an efficacious nanoparticle delivery
system, it’s important to have an understanding of how each component of the nanoparticle
system interacts with the drug. Although CDDP is an effective anti-cancer drug it has limited
solubility and dose-limiting side effects including: nephrotoxicity, nausea, vomiting and anemia.
Thus, there is a need to improve the delivery of CDDP.
CaP offers a naturally biocompatible carrier for delivery of CDDP14. A stabilizer
molecule is needed to prevent CaP nanoparticle aggregation and to increase injectability of the
particulate delivery system14,15. We have previously shown that CDDP released from sodium
1

Jessica Lea Woodman – University of Connecticut, 2014

polyacrylate (D) stabilized CaP nanoparticles (nCaPDCDDP) has comparable toxicity to free
drug against cancer cells in vitro16. However, when attached to the nCaPD the CDDP was
significantly less toxic than free CDDP in vitro and our unpublished animal studies revealed a
corresponding lack of in vivo anti-tumor efficacy relative to free drug. CDDP attached to CaP
microparticles without stabilizer did not lose activity, but were not easily injectable, which led to
the conclusion that further work was needed to identify an alternative stabilizer that would not
inactivate the drug. The goal of these studies is to develop a stabilized, injectable calcium
phosphate nanoparticle system for the delivery of CDDP that releases active drug and can
furthermore be targeted to therapy resistant cancer cells. Therapy resistant cells have emerged as
important target and in breast cancer those cells have a CD44high/CD24-/low phenotype17–19. CD44
is the receptor for hyaluronic acid, which is a widely used non-toxic biomaterial that could be
used as a stabilizer of calcium phosphate when modified to contain carboxylate groups, such as
carboxymethyl hyaluronic acid (CMHA)20. The envisioned biocompatible nanoparticle system
may one day impact the longevity of cancer patients by enabling the sustained delivery of higher
doses of CDDP directly to the tumor and the subset of therapy resistant cells through
intratumoral injections with less toxicity.

Aim #1: Select a stabilizer that achieves a highly drug loaded, stable nanoparticle delivery
system. Hypothesis: If a molecule is a successful stabilizer for a calcium phosphate nanoparticle
delivery system for CDDP then CDDP will bind to the stabilized nanoparticles and will be
released slowly. In addition to the previously published stabilizing molecule sodium polyacrylate
(Darvan ® 811, D); sodium citrate (CIT)21 and carboxymethyl hyaluronic acid (CMHA)20 were
also tested. Particle size was assessed with dynamic light scattering (DLS), transmission electron

2

Jessica Lea Woodman – University of Connecticut, 2014

microscopy (TEM). X-ray diffraction (XRD) determined structure. Inductively coupled plasma
optical emission spectrometry (ICP-OES) determined Pt content which corresponds to CDDP. In
vitro drug release was performed using a modified USP apparatus 422.

Aim #2: Examine the anti-cancer activity of CDDP loaded stabilized nanoparticles in vitro.
Hypothesis: If the stabilized CaP nanoparticle delivery system does not inactivate CDDP, then
the CDDP loaded nanoparticles will have equal or greater in vitro cytotoxicity than CDDP
alone. Each stabilized nanoparticle delivery system (nCaPxCDDP, where x = D, CIT or CMHA)
made in Aim#1 was analyzed to determine the drug concentration that inhibits proliferation by
50% (IC50) using an MTS assay (Promega CellTiter Aqueous One). nCaPxCDDP and CDDP
reacted with stabilizer was compared to CDDP alone to determine if the stabilizer affects the
drug activity by itself or as part of the nanoparticle delivery system. Surface Plasmon resonance
(SPR) examined the binding of nCaPCMHACDDP and recombinant human CD44-Fc chimera
antibody.

Aim #3: Assess the in vivo anti-tumor effect of CDDP loaded nanoparticles after
intratumoral delivery. Hypothesis: If the nCaPxCDDP releases active CDDP at locally high
concentrations in the tumor environment after intratumoral injections, then nCaPxCDDP treated
mice should have reduced tumor growth rate without systemic toxicity as compared to free drug.
Subcutaneous tumors from mouse and human cancer cells were initiated in the flanks of nude
mice. Tumor volume and animal weight were measured daily after cell injections. Animals were
treated with nCaPxCDDP intratumorally (IT) and, compared to a positive control of CDDP that
can only be administered at a lower dose due to systemic toxicity and solubility limits.
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1.2 Background
In the United States, approximately 1.7 million new cases of cancer were diagnosed in 20132.
Cancer causes one in four disease related deaths in the United States, and an ever aging
population is expected to drastically increase the number of cancer-associated deaths over the
next 20 years. The rate of cancer incidence has declined in the United States since 1975 yet it
was estimated that over 1.6 million new people were diagnosed with cancer in 20132. The
National Institutes of Health estimate that the overall cost of cancer was approximately 201.5
billion dollars, in 200823. This dissertation is focused specifically on treatments for head and
neck cancer and breast cancer because of the large potential benefit to these patients from
localized treatment prior to surgical resection. Tumor reducing treatments could mean normal
tissue is spared and chemotherapy side effects are reduced. The incidence, current treatments and
outlook for each type of cancer is reviewed.
1.2.1 Head and Neck Cancer
Cancer of the head and neck is the 6th most common cancer worldwide24. In 2008, it was
estimated that we spent 3.2 billion dollars on head and neck cancer (HNC) treatment in the
United States25. It is commonly a squamous cell carcinoma found in the oral cavity, nasal cavity,
nasal sinuses, oropharynx, hypopharynx, thyroid, lips, or larynx. HNC is typically linked to
damage from alcohol and/or carcinogens. Recently, human papillomavirus (HPV) has also been
elucidated as a driver for specific types of HNC. It is estimated that 30% of HNCs, specifically
those of the oral cavity/pharynx are associated with HPV with a specific genetic profile linked
with HPV16-E6 oncogene expression26–28. The complex anatomical locations of HNC are a
major consideration during treatment planning for HNC patients. Physicians are tasked with
balancing the tumor control/survival and the patients’ quality of life and overall functionality,
4
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during and following treatment. There are often major complications with eating, breathing,
speaking in addition to disfigurement associated with HNC.
First line therapy is surgical resection but often surgery is very complicated or impossible
because tumors are located close to vital anatomy, like the carotid artery29. There has been some
evidence that neoadjuvant therapy lowers the occurrence of distance metastases, but no benefit in
loco-regional control or survival benefit was found29. Radiotherapy and chemotherapy are the
only options for unresectable tumors, which are often used in combination leading to significant
acute and long term side-effects30. CDDP is the standard chemotherapy for HNC patients which
may be combined with other therapies, yet 50% of patients recur within 2 years following initial
treatment29. This statistic highlights the necessity for advanced therapies to treat HNC.
An injectable collagen gel carrying CDDP and epinephrine (IntraDose) was entered into
several clinical trials for intratumoral therapy against a wide range of solid tumor based cancers.
Separate clinical trials were conducted for the treatment of recurrent metastatic breast cancer and
head and neck cancer, yet both trials failed due to lack of clinical and patient benefit combined
with toxicity31–35. There is currently no clinically approved molecular therapy for the treatment
of HNC. This is in part due to lack of molecular targets. Generally, those that are currently in
clinical trials are known drivers for carcinogenesis being applied to HNC, but are not truly
specific to HNC. The few molecular targets for HNC are epidermal growth factor receptor
(EGFR), vascular endothelial growth factor and small molecules such as PI3 kinase and mTOR.
Inhibitors or monoclonal antibodies have been developed to specifically target these drivers of
cancer. More than 35 clinical trials are being conducted specifically for HNC with targeted
therapies alone or in combination with chemotherapy at varied disease stages36,37. To date, none
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of these approaches have stood out above current clinical practice for tumor shrinkage, mean
survival time or disease free progression.

1.2.2 Breast Cancer
In the United States, 1 in 36 women will die from breast cancer38. The American Cancer Society
estimates that 12% of women in the United States will have invasive breast cancer during their
lives2. Breast cancer risk increases with age and there are specific inheritable mutations that are
strongly linked to susceptibility, in the BRCA1 and BRCA2 genes. Treatment options are
patient specific, but typically include surgical removal of the mass and often radiation therapy39.
Many breast cancers over-express estrogen receptor (ER), progesterone receptor (PR) and/or
human epidermal growth factor receptor 2 (HER-2). Targeted hormone therapies are approved
for patient specific treatment, based on their disease progression and hormone status. It is
estimated that 20-25% of women with invasive breast cancer will be classified as triple-negative,
which means their tumor lacks expression of ER, PR, and HER-240. Triple negative breast
cancers (TNBC) are typically more aggressive and challenging to treat and cannot benefit from
directed hormone therapy.

This sub-type of breast cancer will be focused on within this

dissertation.
Chemotherapy is the first line of defense for TNBC patients, instead of the molecular
therapies directed against breast cancers40. If the cancer recurs, short-term and overall survival is
significantly shorter for those patients than for non-TNBC patients41. Recurrence is hypothesized
to be due to therapy resistant cells within the tumor18,42. Therapy resistant breast cancer cells
have a common phenotype of CD44+/CD24low

43–46

. Two studies examining patient samples

histologically found a correlation between TNBC, CD44+/CD24low and recurrence17,19,47,48. In a
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recent multi-center study, TNBC patients were treated with four cycles of CDDP (not commonly
used to treat TNBC) and 50% of patients had a good response (22% complete pathologic
responses)49.

This is an important finding for the work performed in Chapter 4 of this

dissertation.
In Dr. White’s laboratory, at the University of Connecticut Health Center (UCHC),
human luminal A breast cancer cells, MCF-7s, were serially cultured into mammospheres for 5
weeks, where each week cells were dissociated and placed into a new mammosphere culture.
After 3 weeks, the cells had undergone epithelial to mesenchymal transition (EMT), such that
when placed into two-dimensional culture they displayed a mesenchymal, CD44+/CD24-/low
phenotype, referred to as luminal to mesenchymal switch (LMS) cells 50. This protocol was also
performed with human luminal breast cancer cells, BT-474s.

BT-474 cells have a CD44-

/low

/24high phenotype51,52. After serial mammosphere passages BT-474 cells underwent EMT,

referred to as BT-474m cells, resulting in a mesenchymal phenotype including enhanced
proliferation rate, up-regulation of vimentin, down-regulation of E-cadherin (unpublished data)
and cell surface marker expression of CD44+/CD24-. Importantly, these cells were negative for
ER, PR and HER-2, making them a representative TNBC cell. This work was performed in Dr.
Bruce White’s lab at UCHC and will be published elsewhere.
1.2.3 Intratumoral Chemotherapy
Most cancer treatments, especially chemotherapy, kill healthy cells as well as diseased cells,
leading to debilitating systemic side effects. Physicians currently use systemic chemotherapy to
treat most cancers despite the cancer being in a specific anatomical location53. CDDP for
example is poorly soluble and causes nephrotoxicity, nausea, anemia and other deleterious sideeffects54. Intratumoral chemotherapy is the administration of chemotherapy directly into the
7
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primary tumor, allowing for higher doses to be administered while systemic exposure is greatly
reduced55. Clinicians’ interest in intratumoral drug delivery systems began more than 60 years
ago, yet advances in this technique have been insufficient to make intratumoral delivery a
mainstream practice today56. Early work delivering chemotherapy locally showed little benefit
over systemic treatment, due to local toxicities and frequent complications57–59. The advent of a
delivery system able to control the release of drug at a therapeutic concentration within a tumor
would alleviate these problems and those due to systemic treatment.
Several drug delivery systems aimed at intratumoral delivery of chemotherapeutic drugs,
including CDDP, have been attempted with limited success32,56,60–64. IntraDose, a
collagen/CDDP/epinephrine gel, had initial pre-clinical success, but ultimately failed to obtain
approval for intratumoral treatment of head and neck squamous cell carcinoma from the U.S.
Food and Drug Administration (FDA) due to toxicity and a lack of significant clinical benefit31.
The collagen gel did not control the release of CDDP, leading to the addition of epinephrine (a
vasoconstrictor) in an attempt to keep the CDDP within the tumor. The burst release of CDDP
from the collagen gel ultimately was not controlled by the epinephrine32–34. Particulate
bioceramics offer a non-inflammatory, biodegradable carrier for drug, non-viral gene, and
protein delivery that may be able to overcome the problems of the previous work including
uncontrolled drug release, side-effects due to the drug carrier and accumulation of drug in
healthy tissues65–67. Calcium phosphate microspheres carrying an anti-angiogenic agent delivered
locally to human uterine sarcoma xenografts caused a significant decrease in tumor weight
compared to local treatment with the agent alone68. Calcium phosphate cements (CPCs) have
been studied for local delivery of chemotherapy and concurrent bone healing. CDDP and
caffeine delivered from calcium phosphate cement in a rat model of osteosarcoma significantly
8
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reduced tumor size and mean survival of animals due to an extended release time of drug69.
Delivery of cements and microparticles requires large gauge needles that are not attractive or
common for delivery of drugs, therefore a readily injectable suspension would be more
attractive. As with most local drug delivery vehicles, it is essential that the release of drug be
controlled such release is stably within the therapeutic window to alleviate the necessity of
several doses. If this is not achieved the delivery vehicle may not surpass the effectiveness of the
drug alone.
1.2.4 Nanoparticles for Cancer Therapy
Attachment of drug to a particulate drug delivery system is a tactic that has long been employed
to sustain drug delivery with promising results70,71. Human capillaries are approximately 5 um in
diameter, thus nanoparticles can freely travel throughout circulation72. Nanoparticles are
attractive for the treatment of cancer for many reasons. They can be designed to actively or
passively target tumors. Passive targeting by nanoparticles relies on the enhanced permeability
and retention (EPR) effect, due to leaky tumor vasculature that allows particles to collect within
the tumor. Active targeting of nanoparticles involves the incorporation of a ligand, antibody or
other specified moiety that will specifically bind cancer cell surface receptors with the goal of
cell uptake. Many chemotherapeutics are poorly soluble and have short biological half-lives.
Nanoparticles can be loaded with high concentrations of chemotherapeutic drug increasing their
solubility and often the drugs’ residence time in the body.

In recognition of the vast

opportunities nanoparticles offer for advances in cancer diagnosis and treatment, the National
Cancer Institute (NCI) created the Nanotechnology Characterization Laboratory (NCI-NCL).
Researchers can submit applications to NCI-NCL for pre-clinical characterization and toxicity
testing of their nanoparticles. To date, FDA approved nanoparticle therapies for the treatment of
9
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cancer is limited, due in part to the complexity of each systems’ components and their relative
biological effects6.
Nanoparticles can be synthesized from a wide range of materials including: metals,
natural or synthetic polymers, ceramics or proteins. Liposomes were one of the first drug
delivery technologies developed. Doxil® (Janssen Products, LLC) is an example of an FDA
approved PEGylated-liposomal formulation of doxorubicin. Doxil® is indicated for the treatment
of recurrent ovarian cancer and relapsed or refractory multiple myeloma73. Polyethylene glycol
(PEG) coating of nanoparticles (PEGylation) limits their detection by the immune system,
termed stealth nanoparticles74. Albumin nanoparticles carrying paclitaxel, Abraxane® (Celgene
Corporation), is indicated for the treatment of metastatic breast cancer, advanced non-small cell
lung cancer and recently for metastatic pancreatic adenocarcinoma75.
There has been some success in liposome-based drug delivery systems for cancer therapy
but further effort is necessary to make them inert and long-circulating in blood, able to efficiently
bind and transfer with targeted sites, and able to sustain release of active components after
targeting5,13,74,76,77. Clinical trials have been conducted with a liposomal PEGylated CDDP
delivery system, SPI-77, for the treatment of non-small cell lung cancer as well as recurrent
epithelial ovarian cancer. In both studies patients failed to significantly benefit from the
treatment overall in addition to significant concerns regarding high lipid load combined with
large deposits of platinum in non-diseases tissues throughout the body78,79.

Biodegradable

polymer-based drug delivery systems often have acidic byproducts, which can produce adverse
effects on the body or the drug attached or encapsulated4,60,71,80. Naturally occurring biopolymers
or synthetic biopolymers such as polypeptides can also be employed as drug carriers, but their

10

Jessica Lea Woodman – University of Connecticut, 2014

quality, reliability and the high cost of preparation can often prevent their usage81. These
limitations provide the motivation for continued research in biomaterials for drug delivery.
1.2.5 Polymeric Stabilization of Nanoparticles
Stability is a major concern for nanoparticle formulations. If nanoparticles agglomerate in
suspension, they are no longer nanometer in size and will fall out. The most common approach
to enhancing nanoparticle stabilization is with the addition of polymers and/or surfactants to the
surface of the nanoparticle. PEG is likely the most common polymeric solution to nanoparticle
instability, by steric stabilization with the brush-like corona it creates around particles.
PEGylation is often performed on liposomal formulations where it serves not only as a colloidal
stabilizer but also as a biological stabilizer, allowing the liposomes to avoid opsonization by
serum proteins74,82.
formulation.

Doxil® is an example of an FDA approved PEGylated liposomal

Calcium phosphate nanoparticles carrying genetic material have also been

PEGylated for pH sensitive intracellular delivery of payload10,83. Natural polymers such as
chitosan have been utilized to stabilize nanoparticles. Calcium phosphate has been effectively
stabilized by chitosan for gene transfection and drug delivery84,85.

Additional methods to

stabilize calcium phosphate nanoparticles will be discussed thoroughly in the next section.
1.2.6 Calcium Phosphate Nanoparticles
Significant research has been conducted for the use of CaP as a bone replacement in the form of
cement or particles69,86–88. Due to its inherent biocompatibility, CaP has been elucidated as an
attractive biomaterial for a wide range of applications, such as a vector for gene delivery, probe
diagnostic imaging, or adjuvant for vaccinations84,89–92. They have a high affinity to proteins,
DNA, enzymes and cells giving them great potential as effective delivery vehicles65,83,89,93. The
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reactive crystal surface of calcium phosphate particles facilitates rapid binding of charged and
even neutral molecules to its surface and control of molecule release67,94. Nanoparticle
formulations of calcium phosphate have been shown to effectively transport several types of
molecules across cell membranes94–96.
Particulate CaP can be synthesized via wet precipitation. Original interests in the
controlled synthesis of CaP were to understand and recapitulate the formation of bone and teeth
in vertebrates97. CaP nanocrystals can be synthesized without stabilizer, but careful control of
the precipitation and immediate freeze drying is essential to avoid conversion and
agglomeration66. These nanocrystals are often sintered or otherwise fused together to create
large biomaterial scaffolds, for bone or tooth applications. For drug delivery, Barroug et al.
showed poorly crystalline and amorphous calcium phosphate are more reactive than crystalline
particles due to more surface defects allowing for greater drug adsorption15.
Many approaches have been applied to the synthesis of stabilized CaP nanoparticles
(nCaP). Stabilization has been achieved by incorporating DNA into the precipitated nCaP,
which could then be coated with polymers for enhanced transfection efficiency89,93,95,98. nCaP
can be stabilized by the addition of sodium citrate due to the interactions of the carboxylate
groups of the citrate and the Ca21,99. A range of polymers have also been utilized to stabilize
nCaP during precipitation including: sodium polyacrylate16, PEG-block-poly(aspartic acid)10,
polyethyleneimine100, and carboxymethyl cellulose94,101. Specific applications of calcium
phosphate for delivery of chemotherapeutics have been somewhat limited in comparison to
liposomal and polymeric formulations. Recently, Iafisco et al. reported targeted cellular uptake
of biomimetic apatite nanocrystals carrying doxorubicin, but their in vitro cytotoxicity was not
greater than free doxorubicin102. The same group has shown that biomimetic hydroxyapatite
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nanoparticles can bind and release cationic, anionic and neutral drugs for anti-cancer and
simultaneous bone regeneration applications103. Work in our lab using sodium polyacrylate to
stabilize nCaP for the delivery of CDDP for localized treatment of head and neck cancer will be
further explored in the following chapter. CDDP is bound to nCaP utilizing a cationic, aquated
species of CDDP. The free Cl ions in physiological environments is a driving force for CDDP
release (Figure 1.1 A)14,15. Additionally, CaP is known to dissolve in acidic pH, similar to that
found in the tumor microenvironment and lysosomes within cells (Figure 1.1 B)104–107.
1.2.7 Summary
Treatments for cancer patients can be limited due to anatomical location. Surgical resections for
HNC can be disfiguring and dangerous, and localized radiation causes major side-effects
drastically lowering quality of life for patients30. CDDP is an effective chemotherapeutic, but is
limited due to low solubility and nephrotoxicity. Localized delivery of a high dose of CDDP to
shrink the tumor and minimize side-effects could greatly benefit patients. TNBC patients have
limited treatment options, because their cancer presents with none of the commonly targeted
hormone receptors in standard BC hormone treatments. Localized treatment with a nanoparticle
targeted to CD44+/CD24-/low, therapy resistant breast cancer cells is an attractive approach to
prevent difficult to treat recurrence. Calcium phosphate nanoparticles are biocompatible and
known to bind and release CDDP effectively, but require effective stabilization. Thus this
dissertation evaluates stabilizer candidates for: (1) ability to stabilize nCaP, (2) allow for
biologically active CDDP to release from the nanoparticles, and (3) effectively deliver a local,
high dose of CDDP to tumors in vivo to delay tumor growth while causing fewer side-effects
than systemic CDDP. We demonstrate that localized delivery of chemotherapy remains a
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promising strategy to increase drug effectiveness while decreasing drug side-effects that
negatively impact cancer survivors.

Figure 1.1: Schematic showing the release mechanism for the nCaPxCDDP delivery system. (A)

The presence of Cl- ions is a driving force for CDDP release from nCaP, resulting in re-formation
of native CDDP from the bound aquated form of CDDP (B) In acidic pH, like that within tumors
or in the lysosome, nCaP will dissolve, releasing active CDDP.
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Chapter 2
Sodium Polyacrylate Stabilized Calcium Phosphate Nanoparticles for Delivery of
Cisplatin
2.1 Introduction
Calcium phosphate nanoparticles (nCaP) are an attractive vehicle for the delivery of therapeutics
due to their biocompatibility, low cost, and ease of manufacture15,89,91,108,109. Previous work in
our lab showed that sodium polyacrylate (Darvan® 811, D) could effectively stabilize nCaP
(nCaPD) , and allow binding cisplatin (CDDP), a commonly used clinical chemotherapeutic to
form a drug delivery system for CDDP, nCaPDCDDP16. The stabilization of nCaP is achieved
by interaction of the free carboxylate groups in each monomer unit of D with the calcium rich
surface of calcium phosphate. The research described in this chapter builds upon that promising
in vitro data published by Cheng & Kuhn, 200716. Working towards a successful clinical drug
delivery nanoparticle system, it is essential that parameters of synthesis be controlled and the
resulting product be essentially the same from batch to batch6. In addition to batch to batch
consistency, product stability is essential to define. Essential characteristics of nCaPDCDDP
include particle size, drug loading, and cytotoxicity. We therefore examined these parameters in
studies of repeatability & stability, prior to conducting efficacy studies of nCaPDCDDP.
CaP precipitated without stabilizer has been shown to effectively delivery CDDP, but is
not readily injectable. Here we made a similar non-stabilized CaP, microCaPCDDP, to examine
as a positive control. Both nCaPDCDDP and microCaPCDDP were tested against three different
cell lines: SCCVII, FaDu and A2780cis. The latter two cell types are examples of CDDP
resistant human cell lines, HNC and ovarian cancer, respectively. It was hypothesized that the
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nanoparticle formulation could overcome CDDP resistance via direct nanoparticle uptake. Yang
et al. recently published CDDP core micelles with a PEGylated corona that could overcome
CDDP resistance via enhanced cellular uptake, followed by drug release intracellularly110. The
overall goal for this chapter was to establish a preclinical data set for the treatment of head and
neck cancer (HNC) with nCaPDCDDP administered intratumorally (IT) to suppress tumor
growth and decrease toxicity associated with CDDP administered systemically. Efficacy against
a mouse HNC cell line was examined in vivo and compared to CDDP administered systemically
(intraperitoneal, IP) or locally (intratumoral, IT).
2.2 Materials and Methods
2.2.1 Materials
Ca(NO3)2·4H2O (Sigma C1396), K2HPO4 (Sigma S1804), , Pt(NH3)Cl2 (CDDP, Sigma P4394),
and AgNO3 (Silver Nitrate, Sigma S6506) used to prepare the nanoparticles were all purchased
from Sigma-Aldrich, (St. Louis, MO). Sodium polyacrylate, Darvan® 811 (D), was supplied by
R.T. Vanderbilt (Norwalk, CT). CDDP was prepared at 1 mg/mL in sterile saline (0.9% NaCl),
unless otherwise noted. The molecular structure of D is shown in Figure 2.1.
Murine squamous cell carcinoma of the head and neck, SCCVII cells were kindly
provided by Dr. C. Johnson at the Roswell Park Cancer Institute. Cells were maintained in
RPMI 1640 (Gibco 11875), containing 12% heat-inactivated FBS and 1% penicillin
streptomycin. FaDu cells from ATCC and human CDDP resistant ovarian cancer A2780cis cells
were used for intro cytotoxicity evaluation of the nanoparticles. FaDu cells were maintained in
MEM (Gibco 10370) containing 10% heat-inactivated FBS, 1 mM sodium pyruvate (Invitrogen
11360), 2 mM L-glutamine (Invitrogen 25030), 1% penicillin streptomycin. A2780cis cells were
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maintained in RPMI 1640 (Gibco 21870) with 10% FBS and 2 mM L-glutamine where every
third passage contained 1 µM CDDP to maintain CDDP resistance.
C3H/HeJ mice were purchased from Jackson Laboratory, (Bar Harbor, ME) and used for
studies at 6-8 weeks of age.
2.2.2 nCaPDCDDP Production and Optimization
Figure 2.2 is a graphic representation of the nCaPD production procedure. nCaPD was made via
precipitation of equimolar and equal volume solutions of Ca(NO3)2 and K2HPO4, where the
phosphate solution was manually poured into a stirred calcium solution, followed by the addition
of 1.67(v/v)% Darvan®811 (sodium polyacrylate). During studies to optimize the nCaPDCDDP
formulation, batches were made using half the concentration of D that is in the standard
formulation, these particles are referred to as: nCaPD/2CDDP. Additionally, batches were
synthesized that contained no stabilizer, creating CaP microcrystals (microCaP). For
nCaPD/2CDDP and microCaP all procedure steps following precipitation remained the same as
normal nCaPDCDDP preparation. Mixing was allowed to continue for one hour. nCaPD was
collected via centrifugation, washed with ultrapure H2O then centrifuged again. Aquated CDDP
(Aq CDDP) was made as previously reported16. Briefly, 90 mM AgNO3 was reacted with a 1
mg/mL CDDP solution prepped in Ultrapure water at a 2:1 molar ratio. The reaction was allowed
to occur for at least 24 hours, after which precipitate was removed with three centrifugation steps
followed by 0.2 µM filtration. Binding solution was prepared as a 1:1 solution of 1:1 Aq CDDP
at 1 mg/mL to 20 mM potassium phosphate buffer (KPB) pH 6.8. Binding of the Aq CDDP to
nCaPD was allowed to occur for ~24 hrs. at 37°C at a concentration of 4 mg nCaPD per 1 mL
binding solution. Binding solution was removed via centrifugation and a wash step with 10 mM
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KPB, followed by a final centrifugation to concentrate the nCaPDCDDP. nCaPDCDDP was
diluted with ultrapure H2O to form a suspension injectable through a 25G needle. CDDP content
was determined by inductively coupled plasma-optical emission spectroscopy (Perkin Elmer®
Optima™ 5300 DV, ESIS Inc., Cromwell, CT).
2.2.3 nCaPDCDDP Physical Characterization
Transmission electron microscope (TEM) images were taken using a Hitachi H-7650 TEM
(Hitachi High-Technologies Canada, Inc., Toronto). TEM samples were prepared by sonicating
the particle suspension and diluting the suspension 26x in 10 mM citrate solution then 10x in
70% ethanol. A 5 uL sample was placed on a formvar carbon coated 300 mesh Cu grid. Sample
sat for 1min and then any excess solution was removed using filter paper. Prior to imaging the
sample completely dried in air for 5 min. Samples were imaged at 80 kV with the TEM. X-Ray
diffraction (XRD) was performed on lyophilized nCaPD using a Bruker AXS D2 Phaser (Cu
radiation, λ =1.54184 Å) (Bruker Corp., Germany). Particle size analysis was performed using a
90 Plus Particle Sizer (Brookhaven Instruments, NY). Drug loading (ug CDDP/mg nCaPD) was
determined by Pt analysis of the suspension for ug CDDP and drying 3 replicates of 100 uL
nCaPD CDDP suspension for ~24 hrs at 37°C to determine the mg nCaPD in 100 uL suspension.
2.2.4 nCaPDCDDP In Vitro Drug Release Studies
Two in vitro drug release studies were performed. One was performed using a ready to use
dialysis device, (Float-A-Lyzer® G2, Spectrum Laboratories Inc., Rancho Dominguez, CA),
with a molecular weight cut off of 100 kD. 0.55 mL of nCaPDCDDP suspension (CDDP
concentration of 4 mg/mL) was loaded in to the dialysis device and placed in 22 mL of 10 mM
PBS. The pH of the PBS was adjusted to 6.8 to mimic an acidic tumor microenvironment.
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Beakers were capped, placed on an orbital shaker, and incubated at 37°C. Release samples were
drawn at 1h, 6h, 1d, 3d, 5d, 7d, and 14d. At each time point 5 mL of release solution was taken
and replaced with 5 mL of fresh PBS. The second release study used a modified USP apparatus 4
with a dialysis sac22. 0.4 mL of nCaPD/2CDDP suspension (CDDP concentration 5 mg/mL) was
placed into the dialysis sac and 40 mL of 50 mM PBS, pH 6.8 was used for release media.
Samples were removed in 4 mL volumes at 4, 6, 12 hr, 1, 3, 5, 7 and 9 days. CDDP content in
the release solution was determined by inductively coupled plasma-optical emission
spectroscopy (Perkin Elmer® Optima™ 5300 DV, ESIS Inc., Cromwell, CT).
2.2.5 Cytotoxicity
Cytotoxicity experiments were conducted using SCCVII cells plated in 96 well plates at 20,000
cells/mL with 50 uL suspension per well. Cells were allowed to proliferate for 24 hours
following which drug was added in 50 uL volumes. The following groups were examined:
CDDP in saline, Aq CDDP, D alone, nCaPD, nCaPDCDDP and released drug from nCaPDCDDP
at 3 days (nCaPDCDDP (R)). Each group was serially diluted 1:3 across the plate using PBS.
Cells were assayed 48 h after adding drug using in an MTS assay (CellTiter 96® AQueous One,
G3580, Promega Corp., Madison, WI), where metabolic activity was determined using a
Spectramax Plus384 Spectrophotometer (Molecular Biosciences, Sunnyvale, CA) at an
absorbance of 490nm. Background correction was performed for any CaP treated groups due to
background interference. Background plates were handled in the same manner as test plates, but
no CellTiter reagent is added prior to reading the absorbance. To determine the IC50 (50%
inhibitory concentration) a non-linear regression curve fit analysis was performed with at least
four replicates per group. All cytotoxicity experiments were repeated at least twice. Statistical
significance was determined.
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To compare the cytotoxicity of CDDP, nCaPDCDDP, and microCaPCDDP three
difference cell lines were examined: SCCVII, FaDu and A2780cis. The latter two cell types are
examples of CDDP resistant human cell lines.
2.2.6 Process Repeatability, Product Stability and Stabilizer Optimization
To assess the repeatability of the production of nCaPDCDDP three separate batches were made
within one week’s time following the procedure as described in section 2.2, using the same batch
of Aq CDDP, all other components were prepared fresh. To assess stability, nCaPDCDDP made
two (5-11-09) and three years (9-8-08) prior was compared to a batch of nCaPDCDDP made
freshly. In an approach to reduce the amount of D added to create particles, batches were made
using 0.835% (v/v)% D to produce nCaPD/2CDDP which was compared to a standard batch of
nCaPDCDDP. For each of these measures drug loading, particle size and IC50 value against
SCCVII cells were examined.
Findings from the initial repeatability study, led to modification to the synthesis and Aq
CDDP binding procedure. The graphic representation of the changes to the synthesis procedure
is in Figure 2.3.

Three batches of nCaPD were pooled prior to rinsing with H2O. After

centrifugation, the particles were resuspended in binding solution and split into three tubes for
overnight binding. All remaining steps were performed as described previously.
2.2.7 nCaPDCDDP In Vivo Maximum Tolerable Dose Study
An initial maximum tolerable dose (MTD) study was performed in 10-12 week old C3H/HeJ
female mice. Tumors were initiated intradermally using 7 x 104 SCCVII cells in 20 uL at a
concentration of 3.5 x 106 cells/mL. The MTD was defined for the purposes of this study as the
maximum dose that could be administered to a mouse that will result in less than 15% weight
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loss. Each mouse received one, intratumoral (IT) injection of the nanoparticle suspension via a
25-gauge needle; (2-6 mice/group) where groups included: 10, 14, 18, and 23 mg/kg
nCaPDCDDP. Mouse weight was monitored daily for twelve days, (by day 8 all mice had
recovered from the normal initial weight loss seen with CDDP doses in the first few days, or had
exceeded 15% weight loss). Mice exceeding 15% weight loss were euthanized.
A second MTD study was conducted in 12 week old female CH3/HeJ mice without
tumors. All doses were administered once, subcutaneously. Three animals were in each group.
Groups were as follows: 9 mg/kg CDDP, 9, 18, 23 and 27 mg/kg nCaPDCDDP.
2.2.8 nCaPDCDDP in vivo anti-tumor efficacy and toxicity studies
C3H/HeJ mice were inoculated with 5x105 SCCVII cells in 20 uL of 2.5x106 cells/mL PBS
intradermally in the right rear flank via a 25-gauge needle. A total of 42 female, 8 week old,
C3H/HeJ mice were included in the study, (6 mice/group, 7 groups). Tumors were measured
daily using digital calipers to calculate the tumor volume as follows: V = W2 * L * 0.4, where W
= width, L = length, and V = volume.
When tumor volume reached 100 ± 20 mm3 animals were enrolled into treatment groups
as follows: 20 µL of saline (IT), 10 µL of nCaPD (IT), 6.5 mg/kg CDDP (IT), 6.5 mg/kg CDDP
(IP), 6.5 mg/kg nCaPDCDDP (IT), or 12 mg/kg nCaPDCDDP (IT). Systemic toxicity was
evaluated by weight change and overall grooming/appearance.

Tumor volume and mouse

weight were monitored daily. Mice were euthanized due to significant weight loss (> 15%), a
tumor length measurement greater than 20 mm, or completion of the study (day 30).
The efficacy study was repeated with modifications due to fast growing necrotic tumors
in the first study. 12 week old C3H/HeJ mice were injected subcutaneously with 4x104 SCCVII
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cells in 50 uL of a 80% BD Matrigel (Franklin Lakes, NJ) and 20% cells + base media. 32 mice
were entered into treatment groups when their tumor volume reached 160 ± 10 mm 3 with 6
mice/group. The groups were as follows: 50 uL Saline (IT), 10 mg/kg CDDP (IP), 2.2 mg/kg (50
uL) CDDP (IT) and 11 mg/kg nCaPDCDDP (IT). The volume of 50 uL was an estimate based
on clinician collaborator suggestion to administer only what would be feasible to administer to a
solid human tumor. This is considered to be 20% of the total tumor volume111,112. Here that
would have been a volume of 30 uL, but the dose of CDDP that could be administered in a 30 uL
volume was very low. We therefore used 50 uL which is approximately 31% of the tumor
volume at time of treatment. All animal experimental procedures were approved by the Animal
Care and Use Committee of the University of Connecticut Health Center, (Farmington, CT).
2.2.9 In Vitro Cytotoxicity Assessment of Darvan, due to Toxicity Shown In Vivo
Due to unforeseen weight loss to animals administered 11 mg/kg nCaPDCDDP (IT) compared to
10 mg/kg CDDP IP, in vitro cytotoxicity testing was employed. We examined the toxicity of D
alone against SCCVII cells. The D was prepared at a concentration of 65 mg/mL. This
concentration was picked based on thermogravimetric analysis of nCaPD, which revealed nCaPD
is approximately 27% D by weight. We then based our calculations on the average mg nCaP D in
the top concentration of nCaPDCDDP: used in the top concentration of cytotoxicity tests relative
to CDDP. Additionally, SCCVII (murine HNC), FaDu (human CDDP resistant HNC) and
A2780cis (human ovarian CDDP resistant cancer) cells were used to examine the cytotoxicity of
nCaPDCDDP compared to CDDP, Aq CDDP and microCaPCDDP.
2.2.10 Statistical Analysis
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Statistical analysis was performed using an unpaired t-test for comparison of two batches. When
comparing three or more batches a one-way ANOVA was used with either a Tukey (when
comparing all groups to one another) or Dunnet (when comparing test groups to a control group)
post-test. A P-value of less than 0.05 was considered statistically significant. Data is presented
as a mean value with its standard deviation indicated (mean + SD).
2.3 Results
2.3.1 Physical Characterization of nCaPDCDDP
Transmission electron microscopy (TEM) (Figure. 2.4 A and B) and particle size analysis via
dynamic light scattering showed that nCaPDCDDP in suspension form small aggregates with an
average size of 150 ± 40 nm. Average drug loading of the suspension is 75 + 10 µg CDDP/mg
nCaPD. XRD of lyophilized nCaPD shows a poorly crystalline hydroxyapatite (HA), Figure
2.5113.
2.3.2 nCaPDCDDP In Vitro Release Studies
The release profile of the nCaPDCDDP using a Float-a-Lyzer® device in PBS, pH 6.8, at 37° C
can be seen in Figure 2.6 A. In comparison, in vitro release of CDDP from nCaPD/2CDDP was
performed using a United States Pharmacopeia (USP) apparatus 4 modified with a dialysis
adapter (Figure 2.6 B). nCaPDCDDP and nCaPD/2CDDP show continuous in vitro release.
nCaPDCDDP released 47% of the total CDDP bound after 12 days in the Float-A-Lyzer®
system. A burst release was exhibited in the first 3 days, with slower, continuous release out to
day 12. After 9 days in the modified USP apparatus 4 nCaPD/2CDDP released 76% of the total
CDDP bound. Again there was a burst release over the first 3 days, followed by a tapering of
release over the remainder of the experiment.
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2.3.3 Cytotoxicity
Figure 2.7 A, shows a non-linear regression curve fit analysis for a CDDP cytotoxicity
experiment, with four replicates. Figure 2.7 B shows an example of background correction when
examining nCaPDCDDP. The blue line represents the original data measured from the test plate
including cells, nCaPDCDDP treatment and CellTiter 96® AQueous One reagent after 4 hours of
incubation. The green line is the background plate that includes cells and nCaPDCDDP treatment.
These absorbance values were then subtracted from the original data to result in the pink line
which represents the corrected data. The corrected curve is what is used to calculate the IC50.
The carrier alone, nCaPD, did not show any significant toxicity at a concentration of 20 ug/mL
that matches its average concentration in nCaPDCDDP at the IC50 relative to CDDP (Figure
2.8).
The in vitro cytotoxicity of nCaPDCDDP and the released CDDP from nCaPDCDDP
(nCaPDCDDP) were compared to CDDP and Aq CDDP against SCCVII cells using an MTS
assay. The respective curves are plotted in Figure 2.9 A and the calculated IC50 values are
plotted in Figure 2.9 B. CDDP released from nCaPDCDDP has the same cytotoxicity as CDDP
alone and Aq-CDDP. nCaPDCDDP was significantly less cytotoxic than CDDP (P < 0.0001).
2.3.3 Process Repeatability, Product Stability and Stabilizer Optimization
The relative stability of batches of nCaPDCDDP was examined. The particle size of batches
stored for 2 or 3 years was significantly larger (152 & 158 nm, respectively) than that made
freshly (125 nm)(P < 0.0001) (Figure 2.10 A). The drug loading also varied with one batch
having significantly lower drug loading (63 ug CDDP/ mg nCaPD) than the freshly made control
(87 ug CDDP/ mg nCaPD) (P < 0.05) (Figure 2.10 B). Lastly, the IC50 value of the batch stored
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for 3 years (3.3 ug/mL) was significantly higher than the fresh batch (2.8 ug/mL) (P < 0.0001)
(Figure 2.10 C).
nCaPD/2CDDP synthesized using half the concentration of D compared to nCaP DCDDP
created significantly smaller nanoparticles, 120 nm vs 125 nm (P = 0.0213) (Figure 2.11 A), with
a significantly higher drug loading 105 vs 87 ug CDDP/ mg nCaPD (P = 0.0056) (Figure 2.11 B).
There was no statistical difference between the IC50 values against SCCVII cells 2.8 vs 3 ug/mL
for D/2 (Figure 2.11 C).
The batch to batch repeatability was examined by comparing three separately synthesized
batches using particle size, drug loading, yield and IC50 values against SCCVII cells. Batches
were labeled: nCaPDCDDP 1, nCaPDCDDP 2 and nCaPDCDDP 3 and all results are listed in this
order. The yield varied from batch to batch, 0.8, 0.9, vs 1.2 g (Figure 2.12 D and E), no statistics
could be performed. Interestingly, the yield did not follow the same trend after Aq CDDP
binding: 1.1, 1.5, vs 1.4 g. No significant differences were found between the three batches in
particle size 168, 202, vs 161 (Figure 2.12 A). The drug loading varied significantly from batch
to batch 66, 124, vs 81 ug CDDP/ mg nCaPD (P < 0.0001) (Figure 2.12 B). The IC50 of batch 2
at 1.5 ug/mL significantly varied from batches 1 and 3, at 1.2 ug/mL (P < 0.001) (Figure 2.12
C).
To address issues with batch to batch repeatability, modifications were made to the
nanoparticle synthesis procedure at shown in Figure 2.3, resulting batches are labeled
nCaPDCDDP A, nCaPDCDDP B and nCaPDCDDP C.

These modifications led to a more

uniform nCaPD and nCaPDCDDP. Although the particle size of batch C was significantly
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smaller than A and B (P = 0.0077) (Figure 2.13 A), the drug loading of all three batches was
uniform. Their resulting IC50 values against SCCVII cells were also uniform (Figure 2.13 C).
2.3.4 nCaPDCDDP In Vivo Maximum Tolerable Dose Study
A maximum tolerable dose (MTD) study was performed in C3H/HeJ mice with tumors. The
MTD is defined as the maximum dose that can be administered to a mouse that will result in less
than 15% weight loss and is a measure of systemic toxicity of the tested materials. The dose of
14 mg/kg nCaPDCDDP IP is the maximum tolerable dose that can be administered to a C3H/HeJ
mouse without experiencing significant weight loss (> 15%). The average weight loss following
a single treatment of 10, 14, 18 and 23 mg/kg nCaPDCDDP IT dose are shown in Figure 2.14 AD, respectively. The 18 and 23 mg/kg dose groups each had one mouse whose weight loss
dipped below the acceptable 15%, therefore these doses are not tolerable.
A second MTD study was performed in CH3/HeJ mice this time without tumors. Animals
were administered treatment subcutaneously, once with three animals per group. In this study 9
mg/kg CDDP (Figure 2.15 E) was compared 9, 18, 23 and 27 mg/kg nCaPDCDDP (Figure 2.15
A-D). Both of the 9 mg/kg treatments were well tolerated. One of the mice receiving CDDP
experienced10% weight loss, but was able to recover. The animals treated with 9 mg/kg
nCaPDCDDP lost a maximum of 5% of the weight at the time of treatment. One of the animals in
the 18 mg/kg group lost more than 15% of her weight and therefore that dose and the higher
doses of 23 and 27 mg/kg were not well tolerated. These higher doses were therefore not
considered for animal efficacy studies. A dose of 12 mg/kg was chosen for the first efficacy
study.
2.3.5 nCaPDCDDP In Vivo Anti-Tumor Efficacy and Toxicity Studies
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The in vivo anti-tumor efficacy of the nCaPDCDDP was evaluated using SCCVII tumors in
CH3/HeJ mice. When tumors reached 100 ± 20 mm3 animals were enrolled into a treatment
group (6 mice/ group) Tumors were treated once with either CDDP intraperitoneally (IP) at 6.5
mg/kg or intratumorally (IT) with

saline (20 uL), CDDP (6.5 mg/kg), nCaP D (10 uL) or

nCaPDCDDP (6.5 or 12 mg/kg). The change in tumor volume and mouse weight was evaluated
for 20 days post treatment, (Figure 2.16 A - F). 6.5 mg/kg CDDP IT resulted in delayed tumor
growth with one tumor completely going away and two not growing beyond their volume at
treatment (Figure 2.16 D). The IT dose of CDDP was significantly more effective at delaying
tumor growth than the same dose delivered IP (Figure 2.17). As expected, saline IT and nCaPD
IT (no CDDP) had no effect preventing tumor growth. A one-way ANOVA was performed
comparing average tumor volume per group for each day. On day 6 following treatment 12
mg/kg nCaPDCDDP, 6.5 mg/kg CDDP IP & IT were significantly more effective at delaying
tumor growth than the vehicle control (saline) (P < 0.05) (Figure 2.18 A). Additionally, at day 6
it was determined that 6.5 mg/kg CDDP IT was significantly more effective than the same dose
of nCaPDCDDP IT (P < 0.05). No animals in this study lost more than 10% of their weight at
treatment. Maximum weight loss was compared across groups, relative to their respective
maximum weight loss day post-treatment (Figure 2.18 A). Here it was found that nCaPDCDDP
at 12 mg/kg IT caused significantly more weight loss than nCaPD IT (P < 0.05) (Figure 2.18 B).
The in vivo anti-tumor efficacy of the nCaPDCDDP was repeated using SCCVII tumors
in CH3/HeJ mice. In an attempt to slow the growth of the tumors, animals were administered
fewer cells, 4 x 104 in a Matrigel basement membrane, subcutaneously. Animals were enrolled
into treatment groups when their tumors reached 160 ± 10 mm3 in size. There were 6 animals
per group. Groups were: CDDP IP (10 mg/kg), Saline IT (50 uL), CDDP IT (50 uL, 2.2 mg/kg)
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and nCaPDCDDP IT (11 mg/kg). Here CDDP IP at 10 mg/kg was the most effective at delaying
tumor growth (Figure 2.19). A one-way ANOVA was performed comparing the average tumor
volume per group each day. At day 6, CDDP IP was significantly more effective at delaying
tumor growth than Saline and nCaPDCDDP at 11 mg/kg (P < 0.05) Figure 2.20 A. Again the
maximum observed weight loss per group was compared relative to the day it occurred on
(Figure 2.20 A). Importantly, we determined that nCaPDCDDP at 11 mg/kg caused significantly
greater weight loss than CDDP IT (2.2 mg/kg) and Saline IT (P < 0.05), with two animal
dropping below 15% weight loss (Figure 2.20 B). Survival was also plotted for this study
(Figure 2.21). CDDP IP at 10 mg/kg allowed for the longest survival times at 15 days posttreatment. Most animals were euthanized due to tumor volume exceeding nearing 2 cm in
diameter and/or due to necrosis.
2.3.6 In Vitro Cytotoxicity Assessment of Darvan, due to Toxicity Shown In Vivo
The purpose of local intratumoral administration of chemotherapy, i.e. IT, is to lessen systemic
toxicity experienced by the animal or patient. Here the in vivo efficacy studies revealed
unforeseen toxicity from nCaPDCDDP administered IT. This is cause for concern about the
formulation or a component within the formulation. We therefore examined the in vitro
cytotoxicity of D (Figure 2.22 A). We found that doses of D found in nCaPDCDDP are cytotoxic.
The IC50 value of D was 455 ug/mL and the concentration of D estimated to be in nCaPDCDDP
in concentrations typically utilized for cytotoxicity studies is 564 ug/mL. We therefore believe
animals experienced weight loss due to the D in the nCaPDCDDP in addition to the CDDP,
though in cytotoxicity studies nCaPDCDDP is not more effective than CDDP alone.
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To further examine the biological effects of D in nCaPDCDDP, we compared the
cytotoxicity of nCaPDCDDP to CDDP, Aq CDDP and microCaPCDDP to SCCVII (murine
HNC), FaDu (human CDDP resistant HNC) and A2780cis (human ovarian CDDP resistant
cancer) cells (Figure 2.22 C-D). The same trend was found for all three cell types, where
nCaPDCDDP was significantly less cytotoxic than CDDP alone (P < 0.0001). For A2780cis cells
microCaPCDDP was significantly more cytotoxic than CDDP (P < 0.0001).
2.4 Discussion
The research described in this chapter was an effort to validate the synthesis and resulting
properties of nCaPDCDDP, along with assessing it’s efficacy in a murine HNC model. The longterm goal of clinical usage of nCaPDCDDP for the treatment of HNC cannot be realized if the
synthesis of nCaPDCDDP cannot be repeated with comparable batch to batch results. As the
development of nanoparticle systems progress, it is essential to take into consideration the scaleup of production from the bench top to clinical and eventually commercial scale. The FDA has
issued Guidance for Industry: Liposomal Drug Products and created a nanotechnology task force
in an effort to stay ahead of the advancing technology. Within the document they highlight the
need for control of product manufacture to ensure a repeatable product during scale-up, as
seemingly small processing parameters can drastically change the resulting product 114. In this
study, we employ a bottom-up approach to form nCaPDCDDP, made by precipitation of calcium,
phosphate, and sodium polyacrylate (D), which was then reacted with CDDP. We found that
from batch to batch nCaPD differs in yield and particle size because of lack of control over the
precipitation with manual addition of components. The variability in particle size likely
contributes to the variability in drug loading. We were able to minimize the variability by a
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minor modification to the nCaPD protocol. Creation of a combined large batch of nCaPD allowed
for uniform nanoparticles, which resulted in uniform drug loading.
In vitro release testing of controlled release parenteral dosage forms such as the locally
administered nanoparticle suspension studied here are essential for quality control, product
development, and in-vitro-in-vivo-correlation (IVIVC).

In comparison to solid oral dosage

forms, extended or controlled release parenterals have complex physicochemical properties and
are varied in their components and resulting release characteristics. Due to these factors, there is
currently no standard compendial method to examine in vitro release from controlled release
parenterals, where many exist for oral dosage forms115.

The Federation International

Pharmaceutique (FIP) / American Association of Pharmaceutical Scientists (AAPS) report on in
vitro release testing of novel dosage forms specifies that release testing methods used to screen
formulations may not be feasible to use for quality control, but should be reevaluated towards
use of a compendial apparatus116.

The release testing methods used for liposomes and

nanoparticle suspensions can be generally categorized into: (1) sample and separate16,117, (2)
dialysis sac84,118,119, or (3) continuous flow22.
Herein, we utilized two types of in vitro release testing. First we used the dialysis sac
method with a Float-a-Lyzer® device which is a commercially available “Ready-to-Use Dialysis
Device.” nCaPDCDDP suspension was loaded into the sac and submerged into release medium
agitated via an orbital shaker, covered in a temperature controlled chamber. Only 45% of bound
CDDP released from nCaPDCDDP using the Float-a-Lyzer® device. This method is quite
commonly used for initial screening of drug release from nanoparticle formulations, but has
several drawbacks. Due to their high surface area and small particle size, nanoparticles can
release drug rapidly. When using a dialysis based method it is assumed that there is not a
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significant resistance in diffusion of drug across the dialysis membrane. Zambito, Pedreschi and
Di Colo showed that diclofenac released near completely from chitosan nanoparticles within an
hour into the medium within the dialysis sac, but the dialysis membrane limited diffusion into the
receiving medium120. Diclofenac has a similar molecular weight to CDDP used here, 296 versus
300 g/mol, respectively. This study used a significantly smaller molecular weight cut off than
we used in our study, which may have less of an effect on diffusion, 12 kDa versus 100 kDa.
Additionally, high variation can be found in this method for reasons including: limited agitation
within the dialysis tubes and high density of nanoparticles in the small volume of the dialysis
tube, slowing diffusion121.
For these reasons, we sought a more accurate and repeatable method to perform in vitro
release testing. Bhardwaj and Burgess developed a novel dialysis adapter to modify the United
States Pharmacopoeia (USP) apparatus 4 for in vitro release testing of colloids22. Where they
showed the modified USP 4 apparatus could discriminate between different liposomal
formulations where dialysis sac methods could not, likely due to sufficient agitation within the
sample cell. Also of importance, sample replicates had low variation. Here we found the
modified USP apparatus 4 allowed for 78% of CDDP bound to nCaPD/2CDDP to release. A
majority of the CDDP was released in the first 72 hours, with 59% of drug releasing in this time.
Importantly, we determined the CDDP released from nCaPDCDDP was as cytotoxic as CDDP
against SCCVII cells, meaning active CDDP is released from the formulation.
CaP is inherently biocompatible, as it is a major constituent of bones and teeth109,122.
When synthesized via wet precipitation, CaP will form microcrystals. These microcrystals
effectively bind and release CDDP14, but cannot be easily injected using a 25G needle.
Additionally, microparticles are too large to pass through the circulatory system70,123. Here the
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addition of sodium polyacrylate halts the precipitation process leading to nanoparticles 150 nm
in diameter on average.

A polyacrylate formed the arms of a star shaped polymeric

nanoconjugate to deliver CDDP, which was shown through in vitro cytotoxicity testing of the
conjugate to be significantly less cytotoxic than CDDP alone against several types of cancer
cells124. Here similar results were found with nCaPDCDDP, but the lessened cytotoxicity was
not as pronounced and we know the released CDDP is effective. This lessened cytotoxicity we
believe is due to the short time frame of the cytotoxicity test, where free drug can readily diffuse
into cells and nanoparticles would require drug to release or cellular uptake to cause cell death.
Additionally, it has been shown that positively charged particles are more readily taken up by
cells95 and nCaPDCDDP is negatively charged thus limiting cellular uptake.
The goal of intratumoral delivery of chemotherapy is to localize a higher dose of drug at
the tumor site while causing less systemic toxicity, for enhanced tumor reduction. That is the
focus of our delivery mechanism. Many other nanoparticle formulations are administered
systemically and hypothesized to enhance drug delivery based on the EPR effect 76. This method
has proven effective for some formulations resulting in approval by the FDA. Doxil ® is an FDA
approved liposomal formulation of doxorubicin. Doxil is readily used clinically to treat recurrent
ovarian and relapsed multiple myeloma73. STEALTH® liposomal CDDP (SPI-77), using the
same liposomal formulation as found in Doxil, was quickly entered into several clinical trials in
patients with advanced cancers, finding no clinical efficacy because drug could not release from
the liposome in vivo78,79,125–127. These findings highlight the significant problem of insufficient
characterization of nanoparticle system components and their interactions with carried drug both
physico-chemically and biologically prior to clinical efficacy testing. Importantly, the
nanoparticle materials should not incur long-term deleterious effects on the patient. Patients
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treated with SPI-77 incurred a significant increase in cholesterol (lipid) levels. Similarly, Doxil ®
is not recommended for patients with a history of heart disease due to lipid load associated with
treatment.
The toxicity experienced by animals treated with 11 mg/kg nCaPDCDDP was not
expected. Though not significantly, the toxicity surpassed that of 10 mg/kg systemic CDDP. The
overall goal of intratumoral delivery of CDDP via nCaPDCDDP was to diminish systemic
toxicity experienced. This prompted cytotoxicity testing of D alone, which showed that at
concentrations found in nCaPDCDDP, D is cytotoxic itself. This explains the toxicity experience
by the animals in the efficacy study.
Another noteworthy point of discussion is that SCCVII tumors are extremely aggressive.
Within 10 days following vehicle treatment animals needed to be euthanized due to excessive
tumor growth as per the Animal Care Committee guidelines at UCHC. This was found in other
labs as well63,128. Even with CDDP at the MTD tumors grew frenetically causing loss of animals
in the treatment group after as little as 10 days. In vitro SCCVII cells are considered a CDDP
sensitive cell line, yet in vivo their aggressive phenotype overcomes any CDDP sensitivity. For
future studies evaluating new therapeutics a less aggressive model would be better to use to limit
large tumor burden and extend animal survival in negative control groups.
2.5 Conclusions
This study showed nCaPDCDDP can be made with batch to batch repeatability and retains
particle size and biological activity after 3 years of storage.

The CDDP released from

nCaPDCDDP is as biologically active as freshly prepared CDDP, in vitro. In vivo nCaPDCDDP
was ineffective at delaying tumor growth in comparison to a lower dose of CDDP administered
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IT.

IT delivery of CDDP was repeatedly effective at delaying tumor growth of the very

aggressive SCCVII tumors. This finding may have clinical relevance and will be studied further.
From these studies it was determined that D is an effective stabilizer of CaP, but negatively
impacts biological activity of CDDP and is toxic. For these reasons, other stabilizers will be
researched for the nCaPxCDDP delivery system.
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Figure 2.1 Molecular structure of sodium polyacrylate (Darvan® 811, D).
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Figure 2.2 Graphic representation of nCaPxCDDP synthesis. Steps follow from left to right.
After the final wash with KPB, particles are resuspended in sterile, deionized water.
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Figure 2.3 The nanoparticle synthesis method represented in Figure 2.2 resulted in large batch to
batch variability of particle size and drug loading. The nCaPDCDDP synthesis procedure was
modified to achieve a more uniform nCaPD, prior to CDDP binding. This is a graphic
representation of the modifications to the nCaPxCDDP synthesis steps. Three 1 L batches were
made and pooled prior to washing. The pooled nCaPD was washed, resuspended in CDDP
binding solution and split into three tubes for overnight binding.
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Figure 2.4 TEM images (A) nCaPD deposited directly on the grid, and (B) nCaPDCDDP directly
deposited on the grid, showing 20-30 nm particles agglomerated into larger clusters of particles
120-180 nm in diameter.
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Figure 2.5 X-ray diffraction spectra (Cu radiation, λ =1.54184 Å) of lyophilized nCaPD (top
solid line) compared to hydroxyapatite standard (JCPDS, #09-0432) (bars). The match between
the broad peaks of the nCaPD with the standard indicates it is poorly crystalline hydroxyapatite.
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Figure 2.6 In vitro release testing shows initial burst release over first 24 hours that tapers as
release continues. Cumulative CDDP released is plotted using the left y-axis, percent CDDP
released using right y-axis. (A) Released CDDP from nCaPDCDDP using a Float-a-Lyzer device
with Mw cutoff of 100 kDa released into PBS, pH 6.8 to mimic acidic tumor microenvironment.
(B) Released CDDP from nCaPD/2CDDP using a USP apparatus 4 modified with a dialysis
adapter, Mw cutoff of 100 kDa released into PBS, pH 6.8.
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Figure 2.7 Cytotoxicity testing analysis using an MTS assay against SCCVII cells. (A)
Demonstration of typical four parameter logistic curve fit for CDDP data. (B) The highest
concentrations of nCaPDCDDP in the assay interfere with absorbance readings at 490 nm. To
correct for this, cells treated with the same concentration of nCaPDCDDP over the same time
period are read on the plate reader without the addition of CellTiter 96® AQueous One reagent,
labeled as Background. These average background absorbance readings are subtracted from the
Original, to find the Corrected curve. The Corrected curve is used for IC50 determination.
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Figure 2.8 Assessment of nCaPD cytotoxicity measured at 490 nm from MTS assay against
SCCVII cells. Arrow shows the concentration of nCaPD in nCaPDCDDP at its IC50 value
relative to CDDP. nCaPD is not cytotoxic atIC50 value of nCaPDCDDP.

42

Jessica Lea Woodman – University of Connecticut, 2014

Figure 2.9 (A) Cytotoxicity curves of CDDP, Aq CDDP, nCaPDCDDP (R) and nCaPDCDDP.
(B) Calculated IC50 values from cytotoxicity curves in A, where data represents 4 replicates.
This data demonstrates that CDDP released from nCaPDCDDP is as cytotoxic as CDDP and Aq
CDDP. nCaPDCDDP is significantly less cytotoxic than CDDP, Aq CDDP and released CDDP
(P < 0.0001).
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Figure 2.10 Stability studies. Freshly prepared nCaPDCDDP was compared to batches that had
been stored for 2 (nCaPDCDDP 5-11-09) and 3 years (nCaPDCDDP 9-8-08). Particle size, drug
loading and IC50 values against SCCVII cells of nCaPDCDDP were found to vary significantly
with time stored. (A) Average particle size of stored batches was significantly larger than freshly
made batch of nCaPDCDDP, ~22% larger (P < 0.0001). (B) Drug loading varied significantly
from a freshly made batch of nCaPDCDDP for one of the two stored batches tested by ~25% (P <
0.05). (C) IC50 value of batch stored for three years was significantly less cytotoxic than freshly
made batch (P < 0.0001).
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Figure 2.11 Effects of reducing D stabilizer concentration by half. To determine if less D
could be utilized to stabilize nCaP, half the concentration was examined. (A) Average particle
size of nCaPD/2CDDP is significantly smaller than nCaPDCDDP (P = 0.0213). (B) Drug loading
of nCaPD/2CDDP is significantly greater than nCaPDCDDP (P = 0.0056). (C) IC50 value of
nCaPD/2CDDP was not significantly different from nCaPDCDDP against SCCVII cells.
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Figure 2.12 Batch to-batch variability assessment. Three separate batches of nCaPDCDDP
were made using exactly the same method. Although particle size was not significantly different
from batch to batch, drug loading and IC50 values were. (A) Average particle size of three
batches of nCaPDCDDP. (B) Each batch had significantly different drug loading than the next (P
< 0.0001). (C) IC50 value of batch two is significantly higher than the other two batches against
SCCVII cells (P < 0.001). (D) Yield varied from batch to batch, before and (E) after CDDP
binding.
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Figure 2.13 Following minor modifications to the nCaPDCDDP outlined in Figure 2.3 synthesis
variation in drug loading and IC50 values were mitigated. (A) Average particle size of three
batches of nCaPDCDDP made using modified method. Batch C was significantly smaller than
the others, but it was only 3% smaller, which is typically acceptable deviation. (B) Differences in
drug loading from batch to batch were mitigated with minor modifications to the synthesis and
binding procedure. (C) Differences in IC50 value against SCCVII cells from batch to batch was
also mitigated.
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Figure 2.14 Maximum tolerable dose of nCaPDCDDP was conducted on CH3/HeJ mice bearing
SCCVII tumors. nCaPDCDDP was administered once intratumorally. Weight loss was monitored
every other day following treatment and shown for each animal. The legend indicates the animal
number. (A) The 10 mg/kg dose was well tolerated. (B) The 14 mg/kg dose caused weight loss
down to 13%, but the animals recovered. (C) The 18 mg/kg dose caused one animal to drop to
13% weight loss and was euthanized due to weight loss and tumor necrosis. (D) The 23 mg/kg
dose caused one animal to drop below the 15% weight loss threshold.
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Figure 2.15 A maximum tolerable dose study for the nCaPDCDDP was conducted on CH3/HeJ
mice and compared to the free drug without nanoparticles. Drug was administered once
subcutaneously. Weight loss was monitored every other day following treatment (A) The 9
mg/kg dose nCaPDCDDP was well tolerated. (B) The 18 mg/kg dose nCaPDCDDP caused
weight loss beyond 15%. (C) The 23 mg/kg dose nCaPDCDDP caused all animals to drop below
the 15% weight loss threshold. (D) The 27 mg/kg dose nCaPDCDDP caused all animals to drop
below the 15% weight loss threshold. (E) The 9 mg/kg CDDP was well tolerated.
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Figure 2.16 Efficacy study of nCaPDCDDP was conducted on CH3/HeJ mice bearing SCCVII
tumors. Animals were treated once when their tumor volume reached 120 ± 20 mm 3. Each graph
shows individual tumor volume (mm3) vs days post treatment for each animal in the group. The
legend indicates the animal number. (A) Negative control, saline IT, did not delay any tumor
growth. (B) Negative control, nanoparticles without drug IT, no significant tumor growth delay
was seen. (C) Positive control, 6.5 mg/kg CDDP IP, was also not effective. (D) Positive control,
6.5 mg/kg CDDP IT, to which response was split between near complete response and nearly no
response. (E & F) nCaPDCDDP IT at two different doses (6.5 and 12 mg/kg). Neither
significantly delayed tumor growth
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Figure 2.17 Efficacy study of nCaPDCDDP was conducted on CH3/HeJ mice bearing SCCVII
tumors. Animals were treated once when their tumor volume reached 120 ± 20 mm 3 and
compared to 9 mg/kg CDDP. Tumor volume, grooming and weight loss were monitored every
other day following treatment.

The graph shows average tumor volume (mm3) for each

treatment group versus days post treatment. The negative control Saline IT (20 uL) had no effect
on tumor growth. nCaPD (10 uL) had no effect on tumor growth. Free drug at 6.5 mg/kg CDDP
intraperitoneally delayed tumor growth. 6.5 mg/kg CDDP caused tumors to stop growing or
disappear in 50% of animals treated. 12 mg/kg nCaPDCDDP did not significantly delay tumor
growth. 6.5 mg/kg nCaPDCDDP did not significantly delay tumor growth.
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Figure 2.18 Efficacy and toxicity study of nCaPDCDDP was conducted on CH3/HeJ mice
bearing SCCVII tumors. Animals were treated once when their tumor volume reached 120 ± 20
mm3. Tumor volume, grooming and weight loss were monitored every other day following
treatment. The average weight loss was determined for each group on each day following
treatment. From that, the maximum weight loss for each treatment group was determined. (A)
The table shows for each treatment group the maximum percent weight loss, the standard
deviation and the day following treatment the weight loss occurred on. (B) At day 6 following
treatment CDDP IT at 6.5 mg/kg was the most effective treatment for the delay of tumor growth
(P < 0.05). 6.5 mg/kg nCaPDCDDP was significantly less effective at delaying tumor growth
than CDDP IT at 6.5 mg/kg. (C) Is a graphical representation of tabulated values in A. 12 mg/kg
nCaPDCDDP caused the most significant weight loss overall.
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Figure 2.19 A repeated efficacy study of nCaPDCDDP was conducted on CH3/HeJ mice bearing
SCCVII tumors. Animals were treated once when their tumor volume reached 160 ± 10 mm 3 and
compared to 10 mg/kg CDDP IP. Tumor volume, grooming and weight loss were monitored
every other day following treatment. The graph shows average tumor volume (mm3) versus days
post treatment (6 animals/group). The negative control Saline IT (50 uL) had no effect on tumor
growth. IP CDDP (10 mg/kg) delayed tumor growth, but ultimately was not effective at stopping
growth of SCCVII tumors.
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Figure 2.20 Repeated efficacy and toxicity study of nCaPDCDDP was conducted on CH3/HeJ mice
bearing SCCVII tumors. Animals were treated once when their tumor volume reached 160 ± 10 mm3 and
compared to 10 mg/kg CDDP IP. Tumor volume, grooming and weight loss were monitored every other
day following treatment. The average weight loss was determined for each group on each day following
treatment. From that, the maximum weight loss for each treatment group was determined. (A) The table
shows for each treatment group the maximum percent weight loss, the standard deviation and the day
following treatment the weight loss occurred on. (B) CDDP IP at 10 mg/kg was the most effective
treatment for the delay of tumor growth (P < 0.05). A dose of 11 mg/kg nCaPDCDDP was significantly
less effective at delaying tumor growth than CDDP IP at 10 mg/kg. (C) Graphical representation of A.
The 11 mg/kg nCaPDCDDP IT caused the most significant weight loss overall.
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Figure 2.21 Survival curve for the repeated murine HNC animal model efficacy study shown in
Figure 2.19. Survival was defined as > 15% weight loss, tumor diameter > 2 mm, or inability to
groom. CDDP IP at 10 mg/kg was the most effective at prolonging survival of the mice.
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Figure 2.22 Darvan ® 811 is cytotoxic at concentrations found in nCaPDCDDP and inhibits
CDDP cytotoxicity. (A) Cytotoxicity curve of D against SCCVII cells. The arrow indicates D
concentration in nCaPDCDDP at top concentration used for IC50 determination (564 ug/mL).
IC50 values from cytotoxicity curves of CDDP, Aq CDDP, nCaPDCDDP and microCaPCDDP
against: (B) SCCVII (C) A2780cis and (D) FaDu cells.
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Chapter 3
Sodium Citrate Stabilized Calcium Phosphate Nanoparticles for the Delivery of
Cisplatin
3.1 Introduction
Head and neck cancer (HNC) patients suffer from many serious side-effects due to treatments
including severe mucositis and complications with eating and talking29. If the tumor is in close
proximity to vital anatomy, like the carotid artery, surgery is very dangerous and often
impossible. For patients with these non-resectable tumors chemo-radiation is the standard of
care, but the 5 year relative survival rate for is only 35%129. There is a desperate need for better
localized treatments for HNC patients.
Calcium phosphate is an attractive inorganic material for drug delivery because it is
biocompatible, resorbable and relatively inexpensive to manufacture65,66,130,131. Calcium
phosphate is an effective carrier for drugs and genetic material, that is readily made via
precipitation, dissolves in acidic conditions, does not incite an immune response and is nontoxic15,67,89,96,109,132. Precipitation of calcium phosphate will result in aggregated microcrystals
unless a stabilizer is added to halt crystal growth and limit aggregation 100. In Chapter 2, we
showed sodium polyacrylate (Darvan ® 811) is cytotoxic in vitro and caused toxicity to animals
as measured by weight loss when administered as a local injection of nCaPDCDDP This chapter
describes the use of sodium citrate to stabilize calcium phosphate for the delivery of CDDP.
Sodium citrate is a known stabilizer of calcium phosphate and is on the Generally Regarded as
Safe (GRAS) list from the Food and Drug Administration21,133,134. The molecular structure of
sodium citrate is shown in Figure 3.1. Sodium citrate stabilized calcium phosphate nanoparticles
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carrying CDDP (nCaPCITCDDP) were physically characterized, tested for in vitro cytotoxicity
and examined for in vivo intratumoral anti-tumor efficacy against a mouse model of human head
and neck cancer.
3.2 Materials and Methods
3.2.1 Materials
The CaCl2 (Sigma C4901), K2HPO4 (Sigma S1804), C6H5Na3O7 2H2O (Sodium Citrate, Sigma
P3786), Pt(NH3)Cl2 (CDDP, Sigma P4394), and AgNO3 (Silver Nitrate, Sigma S6506) used to
prepare the nanoparticles were all purchased from Sigma-Aldrich, (St. Louis, MO). Aq-CDDP
was prepared as described previously [1]. BD Matrigel™ for cell injections was purchased from
BD Biosciences, (San Jose, CA).
Murine squamous cell carcinoma of the head and neck, SCCVII, human hypopharyngeal
carcinoma, FaDu cells from ATCC and human CDDP resistant ovarian cancer A2780cis cells
were used for intro cytotoxicity evaluation of the nanoparticles. FaDu cells were used for in vivo
anti-tumor efficacy. SCCVII cells were maintained as previously mentioned. FaDu cells were
maintained in MEM (Gibco 10370) containing 10% heat-inactivated FBS, 1 mM sodium
pyruvate (Invitrogen 11360), 2 mM L-glutamine (Invitrogen 25030), 1% penicillin streptomycin.
The C3H/HeJ and Nu/J female mice were purchased from Jackson Laboratory, (Bar
Harbor, ME) and used for studies at 6-8 weeks of age.
3.2.2 nCaPCITCDDP Production and Physical Characterization
nCaPCITCDDP synthesis was based on a previously reported method for nCaPCDDP16. To make
the nCaPCIT equal volumes of 30 mM CaCl2 and 30 mM K2HPO4 + 20 mM citrate were mixed by
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adding the phosphate/citrate solution to the calcium and allowed to precipitate for 10 minutes
with stirring. Nanoparticles were collected via centrifugation (12000 rpm for 45 min) and
washed once with MilliQ ® water. The particles were then allowed to adsorb Aq-CDDP for 20
hours. The concentration of the CDDP was determined by inductively coupled plasma-optical
emission spectroscopy (Perkin Elmer® Optima™ 5300 DV, ESIS Inc., Cromwell, CT).
Following binding, the particles were collected via centrifugation, rinsed twice with MilliQ ®
water to remove unbound Aq-CDDP and diluted 2x with 20 mM citrate solution to make a
suspension that was injectable through a 25 gauge needle. All solutions/liquids during the
synthesis process were sterile-filtered with a 0.2 μm filter. The nCaPCITCDDP suspension was
stored at room temperature and shielded from light.
Aq-CDDP content within the nanoparticles was determined by inductively coupled
plasma-optical emission spectroscopy (Perkin Elmer® Optima™ 5300 DV, ESIS Inc.,
Cromwell, CT) on samples of known volume dissolved in 1N of HCl. Particle size analysis
(PSA) was performed via dynamic light scattering technique using a 90 Plus Particle Sizer
(Brookhaven Instruments, NY). Samples were prepared by sonicating the particle suspension and
diluting the suspension 12x in MilliQ ® water. The morphology and size of the particles were
observed by using a Hitachi H-7650 transmission electron microscope (TEM). TEM samples
were prepared by sonicating the particle suspension and diluting the suspension 26x in 10 mM
citrate solution then 10x in 70% ethanol. A 5 uL sample was placed on a formvar carbon coated
300 mesh Cu grid. Sample sat for 1min and then any excess solution was removed using filter
paper. Prior to imaging the sample completely dried in air for 5 min. Samples were imaged at 80
kV with the TEM. X-ray diffraction (XRD) was used to determine changes in crystallinity with
addition of citrate stabilizer and to compare dry vs wet nCaPCIT. Samples of lyophilized calcium
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phosphate without citrate (microCaP), lyophilized nCaPCIT and wet nCaPCIT were analyzed using
a Bruker D2 Phaser.
3.2.3 nCaPCITCDDP In Vitro Drug Release Studies
In vitro drug release studies were performed using ready to use dialysis devices, (Float-ALyzer® G2, Spectrum Laboratories Inc., Rancho Dominguez, CA), with a molecular weight cut
off of 100 kD. 0.55 mL of particle suspension was loaded in to the dialysis device and placed in
22 mL of 10 mM PBS. The pH of the PBS was adjusted to 6.8 to mimic an acidic tumor
microenvironment. The samples were capped, placed on an orbital shaker, and incubated at
37°C. Release samples were drawn at 1h, 6h, 1d, 3d, 5d, 7d, and 14d. At each time point 5 mL
of release solution was taken and replaced with 5 mL of fresh PBS. CDDP content in the release
solution was determined by inductively coupled plasma-optical emission spectroscopy (Perkin
Elmer® Optima™ 5300 DV, ESIS Inc., Cromwell, CT).
3.2.4 Cytotoxicity
Cytotoxicity experiments were conducted using FaDu and SCCVII cells plated in 96 well plates
at 60,000 and 20,000 cells/mL, respectively with 50 uL suspension per well. Cells were allowed
to proliferate for 24 hours following which drug was added in 50 uL volumes. The following
groups were examined with top concentration tested in parentheses: Citrate ( 10 mM), nCaPCIT
(to match nCaPCIT in nCaPCITCDDP ), (CDDP in saline (405 ug/mL), aquated CDDP (466
ug/mL), 20 mM citrate reacted with to Aq CDDP (Aq CDDP-CIT) (458 ug/mL), nCaPCITCDDP
(500 ug/mL), and nCaPCITCDDP release 3d (R) (119 ug/mL). Each group was serially diluted
1:3 across the plate using PBS. Cells were assayed 48 h after drug addition using in an MTS
assay (CellTiter 96® AQueous One, G3580, Promega Corp., Madison, WI), where metabolic
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activity was determined using a Spectramax Plus384 Spectrophotometer (Molecular Biosciences,
Sunnyvale, CA) at an absorbance of 490nm. To determine the IC50 (50% inhibitory
concentration) a non-linear regression curve fit analysis was performed with at least four
replicates per group.
3.2.5 nCaPCITCDDP In Vivo Maximum Tolerable Dose Study
A maximum tolerable dose (MTD) study was performed in 6 month old C3H/HeJ female mice
without tumors (1-4 mice/group) as follows. The MTD was defined for the purposes of this study
as the maximum dose that could be administered to a mouse that will result in less than 15%
weight loss.

Each mouse received one, intraperitoneal (IP) injection of the nanoparticle

suspension via a 25-gauge needle; groups included: 10, 20, 30, and 40 uL injections of
nCaPCITCDDP at a CDDP concentration of 16.7 mg/mL. These volumes result in average doses
of 7.4 mg/kg, 13.3 mg/kg, 20.8 mg/kg, and 24.5 mg/kg respectively, based on individual mouse
weight and CDDP concentration of the nanoparticle suspension. Mouse weight was monitored
daily for eight days, (by day 8 all mice had recovered from the normal initial weight loss seen
with CDDP doses in the first few days, or had exceeded 15% weight loss). Mice exceeding 15%
weight loss were euthanized.
3.2.6 FaDu Tumor Take Rate in Nu/J Mice
To assess the growth parameters of FaDu tumor initiated in Nu/J mice two tumor take rate
studies were performed. This was performed to ensure that tumors will growth at a steady pace,
without growing too fast causing necrosis or too slow such that they regress on their own. The
first study used a BD Matrigel™ to cells in base media ratio of 80:20. Four mice were used per
groups and the groups were: 8 x 105 cells in a 200 uL volume injection or 2 x 105 cells in a 100
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uL injection, in the right rear flank via a 25-gauge needle. Animals were monitored every other
day for 15 days following inoculation.
The second tumor take rate study was conducted again using a 80:20 ratio of Matrigel :
cell suspension. Here groups were: 5 x 106 cells in 200 uL injection (5 animals) and 2 x 106 cells
in 200 uL injection (3 animals), in the right rear flank via a 25-gauge needle. Animals were
monitored every other day for 15 days following inoculation.
3.2.7 nCaPCITCDDP In Vivo Anti-Tumor Efficacy and Toxicity Studies
Two efficacy and toxicity studies were performed using FaDu cells in Nu/J mice. The first study
included 33 mice inoculated with 2x106 FaDu cells in 100μL of a 70 : 30 ratio of BD Matrigel™
: cell-media in the right rear flank via a 25-gauge needle. A total of 33 female, 8 week old, Nu/J
mice were included in the study, (4-6 mice/group, 6 groups). Tumors were measured daily using
digital calipers to calculate the tumor volume as follows: V = (W)2 * L * 0.4. Tumors were
treated once with: 10 mg/kg CDDP IP, 30 µL of saline IT, 20 µL of nCaPCIT IT(without CDDP),
1.4 mg/kg CDDP IT, 13.7 mg/kg nCaPCITCDDP IT or 20.7 mg/kg nCaPCITCDDP IT, when
tumor volume reached 120 ± 20 mm3.
In the repeat efficacy and toxicity study Nu/J mice were inoculated with 2x106 FaDu cells
in 100μL of a 60 : 40 ratio of BD Matrigel™ : cell-media in the right rear flank via a 25-gauge
needle. A total of 28 female, 5 week old, Nu/J mice were included in the study, (7 mice/group, 4
groups). Tumors were measured daily using digital calipers to calculate the tumor volume as
follows: V = (W)2 * L * 0.4, where W = width, L = length, and V = volume.
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Tumors were treated once, intratumorally (IT), with either 30 µL of saline, 30 µL of nCaP CIT
(without CDDP), 1.4 mg/kg CDDP in saline (CDDP IT), or 10 mg/kg nCaP CITCDDP, when
tumor volume reached 140 ± 14 mm3.
For both studies systemic toxicity was evaluated by weight change and overall
grooming/appearance. Tumor volume and mouse weight were monitored at least every other
day. Mice were euthanized due to significant weight loss (> 15%), a tumor length measurement
greater than 20 mm, or completion of the study (day 30). All animal experimental procedures
were approved by the Animal Care and Use Committee of the University of Connecticut Health
Center, (Farmington, CT).
3.2.8 Statistical Analysis
Statistical analysis was performed using an unpaired t-test or Tukey one-way ANOVA, as
indicated in the methods. A P-value of less than 0.05 was considered statistically significant.
Data is presented as a mean value with its standard deviation indicated (mean + SD).
3.3 Results
3.3.1 Physical Characterization of nCaPCITCDDP
A diagram of the nCaPCITCDDP composition is shown in Figure 3.2. Positively charged Aq
CDDP electrostatically binds to negatively charged nCaPCIT to make nCaPCITCDDP. Release of
Aq CDDP is achieved when nCaPCITCDDP is placed in in vitro or in vivo conditions in the
presence of chloride ions which cause the re-formation of native CDDP. Transmission electron
microscopy (TEM) (Figure 3.3 A) and particle size analysis via dynamic light scattering (Figure
3.3 B) showed that nCaPCITCDDP in suspension form small aggregates with an average size of
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180.6 + 19.5 nm. Average drug loading of the suspension is 158.7 + 11.6 µg CDDP/mg
nCaPCIT. These results, in addition with polydispersity, are summarized in Table 3.1. XRD
comparing nCaPCIT as a wet suspension, nCaPCIT lyophilized and microCaP showed
nCaPCITCDDP is poorly crystalline with the major peak occurring at 30º corresponding well with
hydroxyapatite (HA) while microCaP was more crystalline in nature resembling brushite and
poorly crystalline HA (Figure 3.4)

113,135

. The comparison of microCaP with both wet and dry

nCaPCIT clearly demonstrate that crystal growth of CaP was halted by the addition of citrate,
creating nanoparticles with no long order crystal structure.
3.3.2 nCaPCITCDDP In Vitro Release Studies
The release profile of the nCaPCITCDDP in PBS, pH 6.8, at 37° C can be seen in Figure 3.5.
nCaPCITCDDP has continuous in vitro release. A burst release of CDDP was exhibited in the first
24 h, with slower, continuous release out to day 14. Total percent CDDP release after 14 days is
27% based on total CDDP bound.
3.3.3 Cytotoxicity
FaDu cells were used to determine the cytotoxicity of nCaPCITCDDP, nCaPCITCDDP, citrate, Aq
CDDP-CIT, CDDP and Aq CDDP. Non-linear regression curve fit analysis of each of these
treatments is shown in Figure 3.6 A-F. nCaPCIT is not cytotoxic as all concentrations tested had
comparably high absorbance readings (Figure 3.6 D). Citrate alone caused some toxicity at a top
dose of 10 mM (Figure 3.6 C). The in vitro cytotoxicity of nCaPCITCDDP and the released
CDDP from nCaPCITCDDP were determined with FaDu and SCCVII cells using an MTS assay.
The 50% inhibitory concentrations (IC50) are plotted in Figure 3.7. CDDP released from
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nCaPCITCDDP has the same cytotoxicity as CDDP alone and Aq-CDDP. Sodium-citrate when
reacted with Aq CDDP inhibits the cytotoxicity of Aq CDDP.
3.3.4 FaDu Tumor Take Rate in Nu/J Mice
Two tumor take rate studies were conducted in Nu/J mice. The first study used either 2 x 105 or 8
x 105 cells per injection, both of which were determined to be insufficient for regular tumor
growth (Figure 3.8 A. Tumors did not grow steadily and growth tapered after 10 days. The
second tumor take rate study used 2 x 106 or 5 x 106 FaDu cells per injection (Figure 3.8 B). The
early shrinking of tumor volume is due to degradation of Matrigel. Once the Matrigel degrades
tumor growth continues.
3.3.5 nCaPCITCDDP In Vivo Maximum Tolerable Dose Study
A maximum tolerable dose (MTD) study was performed in C3H/HeJ mice without tumors,
(Figure 3.9). The MTD is defined as the maximum dose that can be administered to a mouse that
will result in less than 15% weight loss and is a measure of systemic toxicity of the tested
materials. The maximum tolerable dose that can be administered to a C3H/HeJ mouse without
experiencing significant weight loss (> 15%) is 13 mg/kg nCaPCITCDDP IP. The conjugation of
CDDP to nCaPCIT allows for an increase in MTD compared to CDDP IP (MTD 10 mg/kg). The
results shown in Fig. 13.9 show the average weight loss for the 13.3 and 24.5 mg/kg
nCaPCITCDDP IP dose, in addition to the average weight loss of a 9 mg/kg CDDP IP dose
performed in C3H/HeJ, female, 6 month old mice, but from a previous study.
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3.3.6 nCaPCITCDDP In Vivo Anti-Tumor Efficacy and Toxicity Studies
The in vivo anti-tumor efficacy of the nCaPCITCDDP was evaluated using FaDu human
hypopharyngeal carcinoma tumors in Nu/J. Nu/J mice were injected with 2x106 Fadu cells in
100 µL of 70% Matrigel™ 30% cells and media subcutaneously. Tumors were treated once with:
10 mg/kg CDDP IP, 30 µL of saline IT, 20 µL of nCaPCIT IT(without CDDP), 1.4 mg/kg CDDP
IT, 13.7 mg/kg nCaPCITCDDP IT or 20.7 mg/kg nCaPCITCDDP IT, when tumor volume
reached 120 ± 20 mm3. The change in tumor volume and mouse weight was evaluated for 15
days post treatment (Figure 3.10 A and B). Due to large standard deviations statistical
differences were not detected between the treatment groups. The average tumor volume for
animals treated with 1.4 mg/kg CDDP IT was the lowest, with 10 mg/kg CDDP IP and 13.7
mg/kg nCaPCITCDDP.
For the repeat efficacy and toxicity study , 5 week old, Nu/J mice (Jackson Laboratories)
were injected subcutaneously with 2x106 Fadu cells in 100 µL of 60% Matrigel™ 40% cells and
media. Tumors were treated intratumorally (IT) with varying doses of: saline, CDDP in saline, or
nCaPCITCDDP, once when tumor volume reached 140±14 mm3. The change in tumor volume
and mouse weight was evaluated for 30 days post treatment. 10 mg/kg nCaPCITCDDP IT resulted
in delayed tumor growth (Figure 3.11 A). As expected, saline IT and nCaPCIT IT (no CDDP) had
no effect preventing tumor growth. 10 mg/kg nCaPCITCDDP and CDDP were significantly more
effective at slowing tumor growth than saline or nCaPCIT (Tukey one-way ANOVA). 1.4 mg/kg
CDDP IT was significantly most effective in inhibiting tumor growth. For each treatment group,
average mouse weight loss was not significant (> 15%), (data not shown). Toxicity of the
nCaPCITCDDP was also evaluated via survival (Figure 3.11 B). During the anti-tumor efficacy
study mice were euthanized due to weight loss greater than 15%, tumor necrosis, or having a
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tumor width measurement of 20 mm or greater. Mice treated with 1.4 mg/kg CDDP IT observed
100% survival at day 30. Mice treated with 10 mg/kg nCaPCITCDDP IT resulted in 57% survival
at day 30. Both saline IT and nCaPCIT IT observed 0% survival by day 30.
3.4 Discussion
These results show that sodium citrate is an effective stabilizer for calcium phosphate
nanoparticles carrying CDDP enabling the delivery of a higher dose of CDDP compared to free
CDDP administration with comparable toxicity to the treated animals. The in vitro drug release
profile for nCaPCITCDDP shows a maximum release of 27% of CDDP loaded onto the
nanoparticles is released over the 14 day time period studied.

It was expected that

nCaPCITCDDP would be more effective at treating the tumors locally than a lower dose of free
CDDP, however this was not found in this xenograft model of head and neck cancer. Ultimately
no treatment successfully shrank tumors to their size at treatment nor caused remission, but the
1.4 mg/kg dose of CDDP administered IT resulted in significantly smaller tumors than controls
or nCaPCITCDDP at 10 mg/kg.

This may be due to FaDu cells being moderately CDDP

resistant136,137 combined with the larger tumor volume range at the start of treatment (up to 154
mm3). We examined the biological activity of the CDDP released from nCaPCITCDDP in a
cytotoxicity assay, finding no statistically significant differences between CDDP released from
nCaPCITCDDP, CDDP and Aquated CDDP.
The in vitro release study conducted here was performed using a commercially available,
“ready-to-use” dialysis sac device. This is one of several general methods of studying drug
release that are performed for nanoparticles, including: sample and separate, dialysis sac and
flow through methods116. This method was utilized as a screening method to determine if
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biologically active drug released from the formulation and if so, approximately how much. To
mimic intratumoral conditions we utilized a release medium with pH 6.8138.

This step is

insufficient for development of an in-vitro-in-vivo-correlation (IVIVC), as IVIVC for parenteral
controlled release systems is challenging based on the in vivo site of administration139,140, here
intratumoral. Sink conditions were utilized for our studies and within a dense tumor, there is
limited fluid available and likely sink conditions are not present. At a workshop of the American
Association of Pharmaceutical Scientists (AAPS), Food and Drug Administration (FDA) and
United States Pharmacopoeia (USP) it was stated that a drug release of 80% is desirable from
controlled release parenterals for both safety and the production of an economical dosage
form115. Here we were unable to achieve 80% release from nCaPCITCDDP, this may be due to
lack of sufficient agitation within the dialysis device and high nanoparticle content within the sac
limiting release within and diffusion out of the sac into the release medium120. An additional
method we could have employed to overcome some of these pitfalls would be to perform reverse
dialysis, where the nanoparticles would be suspended within the release medium in the large
vessel and samples removed from within the dialysis sac. This method would alleviate the
challenge posed by nanoparticles being too concentrated within the dialysis sac121. Further
development of this formulation would require a more accurate and reproducible method of drug
release testing. A newly developed method, in Dr. Burgess’ lab at the University of Connecticut,
incorporated a dialysis adapter into the flow through sample cell of a USP apparatus 422. They
were able to discriminate between small variations in liposomal formulations and maintained
minimal variability between replicates. Additionally, this would be a step towards use of a
compendial apparatus for in vitro release testing, which is more analogous to what is performed
for oral dosage forms141.
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The anti-tumor efficacy of the 1.4 mg/kg CDDP administered IT has not been previously
published to our knowledge. This low IT dose of CDDP had not been reported to be sufficient
for delayed tumor growth. The lowest reported dose for CDDP administered IT in a murine
model is 5 mg/kg, which showed minimal tumor growth delays on the order of 3-5 days61,142,143.
We confirmed this finding by repeating the animal study with the same results. Additionally,
FaDu cells are considered a relatively CDDP resistant HNC cell line, with a published IC50 of 6
µM (1.8 µg/mL) 137, and in our lab we found they were even more resistant with an average IC50
of 13.3 µM (4 µg/mL). This is therefore an excellent model for comparison to HNC patients
because it is estimated that 50% of patients with locally advanced HNC will recur with
chemotherapy resistant cancer29. Intratumoral CDDP for the local treatment of HNC may be a
viable alternative for non-resectable tumors, or partially resectable tumors. This further supports
the need to develop an effective local delivery system for CDDP that allows for prolonged
delivery of high local concentrations of biologically active CDDP.
In our lab and others, one of the primary complications to the development of an effective
delivery system is sufficient release of active drug that can penetrate through the tumor mass
once released.

Many different approaches to local therapy for HNC patients have been

researched. Poly-Ɛ-caprolactone blended with poly(DL-lactide-co-Ɛ-caprolactone) sheets loaded
with CDDP were examined in a model of murine HNC where partial surgical resection was
combined with radiotherapy which found the polymer sheet with CDDP and radiotherapy
significantly reduced tumor burden, but the polymer sheet with CDDP alone was not effective
144

. These findings correlate well with many reports of CDDP as a radiosensitizer61,63,145–147. An

injectable polymer, poly (sebacic acid-co-ricinoleic acid ester anhydride), for intratumoral
delivery of CDDP was examined in a model of murine bladder cancer, where the polymer alone
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inhibited tumor growth compared to untreated mice143. The authors speculated the delayed
tumor growth from polymer alone was due to physical injury to the tumor. We examined
nCaPCIT alone IT, but did not cause any delay in tumor growth. We believe this is due to the
superior biocompatibility of CaP as a drug carrier, compared to polymers that often have acidic
degradation by-products.
Nanoparticles for the local delivery of chemotherapy to a tumor have also been
researched.

Li et al., examined block copolymer methoxy poly(ethylene glycol)-

polycaprolactone CDDP nanoparticles against a murine model of liver cancer finding when
delivered IT, the particles were no more effective than CDDP IT at equivalent doses

142

.

Albumin microparticles carrying chemotherapeutic drug mitoxantrone were examined for IT
efficacy against murine breast cancer where the microspheres were not able to increase the MTD
for the carried drug nor were they more effective than free drug alone at increasing animal
survival148. One of the major advantages of a successful IT delivery system is the ability to
deliver a higher dose of drug directly at the site of the tumor. Theoretically the local delivery
offers a therapeutic advantage by limiting systemic drug clearance and drug exposure to healthy
tissues thereby decreasing systemic toxicity57. Here we found that local delivery of very low
doses, 14% of a standard systemic dose of 10 mg/kg for a mouse, of free CDDP was able to
significantly delay tumor growth. This is likely due to the ability of CDDP to more freely
diffuse throughout the dense tumor tissue, versus the nanoparticles which are too large to move
through the interstitial collagen barrier in solid tumors82. Achieving evenly distributed drug using
a nanoparticle delivery system is an ongoing challenge for cancer treatment.
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3.5 Conclusion
In this study we were able to deliver higher doses of CDDP with nCaPCITCDDP IT compared to
systemic CDDP, with comparable toxicity. nCaPCITCDDP caused a significant delay in tumor
growth compared to nCaPCIT and saline controls, but was surpassed by free CDDP administered
IT. Although the anti-tumor efficacy of CDDP IT at 1.4 mg/kg is unexpected relative to the
literature, it is very clinically relevant and therefore important to explore further.
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Figure 3.1 Molecular structure of sodium citrate.

Figure 3.2 Schematic representation of aquated CDDP binding and release from nCaPCITCDDP.
(A) From left to right, CDDP can be made into aquated CDDP, via a reaction with AgNO3.
AgCl precipitate is removed via centrifugation and filtration, leaving a net positively charged
aquated CDDP. nCaPCIT is negatively charged to bind the positively charge aquated CDDP,
resulting in nCaPCITCDDP. (B) In a chloride rich environment, like within the body, a driving
chloride ions act as a driving force for the release of aquated CDDP to reform native CDDP.

72

Jessica Lea Woodman – University of Connecticut, 2014
Table 3.1 Addition of sodium citrate to calcium phosphate precipitation results in nano-sized particles.

Figure 3.3 Characterization of the nanoparticles. (A) TEM image of nCaPCITCDDP, scale bar is
100 nm. Arrow indicates spindle-like citrate molecules. Image shows 20-50 nm particles
agglomerated into larger clusters of particles 120-180 nm in diameter (B) Particle size
distribution of nCaPCITCDDP, bar represents average particle size of 178 nm.
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Figure 3.4 XRD of nCaPCIT suspension (nCaPCIT wet), lyophilized nCaPCIT (nCaPCIT dry) and
lyophilized CaP without citrate stabilizer added during precipitation (microCaP dry) shown from
top to bottom (Cu radiation, λ =1.54184 Å). The circles demonstrate major peaks of Brushite
within microCaP. This demonstrates that citrate halted the long order crystal growth when
present during precipitation, compared to the crystalline peaks observed in microCaP that has no
stabilizer present. For comparison hydroxyapatite standard (JCPDS, #09-0432) (bars) is shown.
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Figure 3.5 nCaPCITCDDP provides sustained delivery of CDDP in vitro. Average percent
CDDP release after 14 days is 27% based on total CDDP available for release. Release studies
were performed using Float-a-Lyzers ® in PBS, pH 6.8, at 37° C, molecular weight cutoff = 100
kDa.
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Figure 3.6 FaDu, human head and neck cancer cells were used to examine the in vitro
cytotoxicity of: (A) CDDP (blue and red colors show replicates), (B) Aq CDDP, (C) Citrate, (D)
nCaPCIT, (E) Aq CDDP – CIT, and (F) nCaPCITCDDP. The highest concentrations of
nCaPCITCDDP in the assay interfere with absorbance readings at 490 nm. To correct for this,
cells treated with the same concentration of nCaPCITCDDP over the same time period are read on
the plate reader without the addition of CellTiter 96® AQueous One reagent, labeled as
Background. These average background absorbance readings are subtracted from the Original, to
find the Corrected curve. The Corrected curve is used for IC50 determination.
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Figure 3.7 Cytotoxicity test of nCaPCITCDDP against (A) FaDu (human HNC) and (B) SCCVII
(mouse HNC) cells in an MTS assay to determine the IC50 value of each treatment. These
studies show that CDDP released from nCaPCITCDDP (nCaPCITCDDP (R)) has the same
cytotoxicity as free CDDP, for both cell types. Reacting sodium-citrate with Aq CDDP
significantly decreases the cytotoxicity of Aq CDDP, for both cell types (P < 0.05).
nCaPCITCDDP was significantly less cytotoxic than CDDP for both cell types (P < 0.05).
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Figure 3.8 Tumor take rate studies performed in Nu/J mice using FaDu cells at two different
concentrations injected in right rear flank of animals. Plots show average tumor volume per
group (mm3) vs number of days since injection of cells, error bars show standard deviation. A
cell number of 2 x 106 was deemed sufficient to initiate tumors, and 2 x 105 or 8 x105 cell number
injections grew too slow. (A) Cell number and injection volume were as follows: 8 x 105 in 200
uL or 2 x 105 FaDu cells in 100 uL volume using Matrigel (4 animals/group). (B) Cell number
injected per 200 uL volume: 5 x 106 or 2 x 106 FaDu cells in Matrigel (5 and 3 animals/group,
respectively).
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Figure 3.9 Weight loss over time with intraperitoneal injections in CH3/HeJ mice. A dose 13
mg/kg nCaPCITCDDP IP is the maximum tolerable dose (MTD) that can be administered IP
without experiencing significant weight loss (> 15%). Delivering CDDP using nCaP CIT allows
for an increase in MTD 13 mg/kg compared to CDDP IP (MTD 10 mg/kg). A dose of 24.5
mg/kg nCaPCITCDDP IP caused significant weight loss and therefore cannot be used for
treatments.
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Figure 3.10 Nu/J mice were injected with 2x106 Fadu cells in 100 µL using Matrigel,
subcutaneously. Tumors were treated with varying doses of: saline, CDDP, nCaPCIT or
nCaPCITCDDP when tumor volume reached 120±20 mm3. No significant differences in tumor
volume were found between groups (A) Average tumor volume (mm3) per group vs. days post
treatment. (B) Average percent weight loss for each treatment group.
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Figure 3.11 A repeat efficacy testing of nCaPCITCDDP in a mouse model of human HNC was
conducted. Nu/J mice injected with 2x106 Fadu cells in 100 µL using Matrigel, subcutaneously.
Tumors were treated once tumor volume reached 140 ± 14 mm3. In this study a lower dose of 10
mg/mg nCaPCITCDDP was administered intratumorally. (A) Graph shows average tumor volume
(mm3) per group versus days following treatment. A 10 mg/kg dose of nCaPCITCDDP resulted
in delayed tumor growth. There were significant differences between Saline and 10 mg/kg
nCaPCITCDDP, Saline and CDDP IT, and 10 mg/kg nCaPCITCDDP and CDDP (P < 0.05). (B)
Survival curve showing percent surviving animals versus days following treatment. Survival
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was defined as > 15% weight loss, tumor diameter > 2 mm, or inability to groom. CDDP IT
allowed for 100% survival to day 30 following treatment. The 10 mg/kg dose of nCaPCITCDDP
allowed for 57% survival to day 30. NOTE: The legend applies to both graphs.
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Chapter 4
Carboxymethyl Hyaluronic Acid Stabilized Calcium Phosphate Nanoparticles for
Delivery of Cisplatin
4.1 Introduction
Triple negative breast cancer (TNBC) patients have limited treatment options because their
cancer does not present with hormone receptors that are effectively targeted for treatment in
breast cancer149. These patients could greatly benefit from a localized treatment that can reduce
the tumor prior to surgical resection, with the goal of lessening chances for recurrence. In this
study calcium phosphate nanoparticles (nCaP) were synthesized with carboxymethyl hyaluronic
acid (CMHA) to determine if CMHA could simultaneously stabilize nCaP and target cancer
cells. CMHA is hyaluronic acid (HA) that has been modified to contain extra carboxylate groups
which are known to interact with Ca and P ions in the during precipitation of CaP134 (Figure 4.1).
Hyaluronic acid (HA) is a major component of the extracellular matrix, a glycosaminoglycan150
and CD44 is a transmembrane molecule that is a major binding and homing receptor for HA.
Therapy resistant breast cancer cells have a common phenotype of CD44+/CD24low. The
presence of these cells in patients with triple negative breast cancer (TNBC) is a poor prognostic
indicator and linked with recurrence48. Therefore the goal of this study was to determine if
nCaPCMHACDDP

could

effectively

target

and

kill

TNBC

cells

with

the

CD44+/CD24lowphenotype.
Calcium phosphate is an excellent biomaterial because it is biocompatible, resorbable and
non-immunogenic94,99,108. In Chapters 2 and 3, we found that both sodium polyacrylate (Darvan
® 811) and sodium citrate effectively stabilize nCaP, but have inhibitory effects on the biological
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activity of cisplatin (CDDP). Here we introduced carboxymethyl hyaluronic acid (CMHA)
during the precipitation process of CaP, creating nCaPCMHA, with the goal of achieving both
nCaP stabilization and biological targeting of CD44. CDDP is an effective anti-cancer drug, but
has dose limiting nephrotoxicity. This study was the first to use carboxymethyl-HA (CMHA) to
stabilize nCaP and simultaneously target CD44 expressing cells while carrying CDDP,
nCaPCMHACDDP. nCaPDCDDP was used as a negative control for evaluating the targeting
capacity of nCaPCMHACDDP. nCaPCMHACDDP was physically characterized using: transmission
electron microscopy (TEM), X-Ray diffraction, particle size analysis and in vitro drug release
studies. The ability of CMHA and nCaPCMHACDDP to bind CD44 was examined using surface
plasmon resonance. Cytotoxicity of nCaPCMHACDDP and the impact of CMHA on Aq CDDP
were examined in vitro against both CD44- and CD44+ cell types. Lastly, an anti-tumor efficacy
study was performed on a model of human therapy resistant TNBC with BT-474m cells.
4.2 Materials and methods
4.2.1 Materials
Calcium lactate pentahydrate (Sigma C8356), K2HPO4 (Sigma S1804), Pt(NH3)Cl2 (CDDP,
Sigma P4394), and AgNO3 (Silver Nitrate, Sigma S6506) used to prepare the nanoparticles were
all purchased from Sigma-Aldrich, (St. Louis, MO). Darvan® 811 was purchased from R.T.
Vanderbilt Holding Company, Inc. (Norwalk, CT). CMHA and HA for these studies was
graciously supplied by Dr. Glenn Prestwich at the University of Utah. Aq-CDDP was prepared
as described previously [1].

BD Matrigel™ for cell injections was purchased from BD

Biosciences, (San Jose, CA).
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Mouse fibroblast cells, NIH-3T3, were purchased from ATCC. They were maintained in
DMEM high glucose (Gibco 11995) with 10% Fetal Calf Serum and 1% penicillin streptomycin.
LMS, BT-474 and BT-474m cells were kindly provided by Dr. Bruce White at the University of
Connecticut Health Center. BT-474 cells were maintained in DMEM/F12 (Gibco 11330) with
10% FBS, 1% p/s and 1% insulin. LMS and BT-474m cells were maintained in DMEM/F12
(Gibco 11330) with 10% FBS, 1% p/s.
J:Nu female mice were purchased from Jackson Laboratory, (Bar Harbor, ME) and used
for studies at 6-8 weeks of age. Female athymic nude mice, 6-8 weeks of age, were obtained
from Charles River Laboratories International, Inc. (Wilmington, MA).
4.2.2 nCaPCMHACDDP Production and Physical Characterization
nCaPCMHACDDP synthesis was based on a previously reported method for nCaPCDDP 16. To
make nCaPCMHA, 30 mM Calcium lactate was added to the reaction vessel and mixing initiated.
To which an equal volume of 30 mM K2HPO4 was added, immediately followed by 2% (w/v)
CMHA (34 kDa) in water at 20% of the total volume of precipitation. Mixing continued for 10
minutes. Nanoparticles were collected via centrifugation (12000 rpm for 45 min) and washed
once with MilliQ ® water. The particles were then allowed to adsorb Aq CDDP for 20 hours.
The nanoparticle s were protected from light on a heated rocker (LAB-LINE® thermorocker,
Barnstead Thermolyne, Dubuque, IA) maintained at 37ºC. Following binding, the particles were
collected via centrifugation, rinsed with 10 mM KPB to remove unbound Aq CDDP and diluted
to approximately 175 mg nCaPCMHACDDP / mL MilliQ water to make a suspension that was
injectable through a 25 gauge needle. All solutions/liquids during the synthesis process were
sterile-filtered with a 0.2 μm filter.

The nCaPCMHACDDP suspension was stored at room
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temperature and shielded from light. nCaPDCDDP was made as previously described except
Calcium Lactate pentahydrate was used instead of Ca(NO3)2·4H2O), to match the calcium used
in nCaPCMHACDDP.
The concentration of CDDP was determined by inductively coupled plasma-optical
emission spectroscopy (ICP-OES) (Perkin Elmer® Optima™ 5300 DV, ESIS Inc., Cromwell,
CT) on nCAPCDDP samples of known volume dissolved in 1N HCl. Particle size analysis
(PSA) was performed via dynamic light scattering using a 90 Plus Particle Sizer (Brookhaven
Instruments, NY). Samples were prepared by sonicating the particle suspension and diluting the
suspension 12x in MilliQ ® water. The morphology and size of the particles were observed by
using a Hitachi H-7650 transmission electron microscope (TEM). TEM samples were prepared
by sonicating the particle suspension and diluting the suspension 26x in MilliQ water then 10x in
70% ethanol. A 5 uL sample was placed on a formvar carbon coated 300 mesh Cu grid. Sample
sat for 1min and then any excess solution was removed using filter paper. Prior to imaging the
sample completely dried in air for 5 min. Samples were imaged at 80 kV with the TEM. X-ray
diffraction (XRD) was used to determine changes in crystallinity with addition of stabilizer and
to compare dry vs wet nCaP. Samples of lyophilized calcium phosphate without stabilizer
(microCaP), lyophilized nCaPCMHA or nCaPD and wet nCaPCMHA and nCaPD were analyzed using
a Bruker D2 Phaser.
4.2.3 nCaPCMHACDDP and nCaPDCDDP In Vitro Drug Release
In vitro drug release studies were performed using a USP apparatus 4 (Sotax CE, Sotax,
Horsham, PA) modified with a dialysis adapter with a molecular weight cut off of 100 kD. A
sample of 0.4 mL of particle suspension was loaded into the dialysis adapter with 100 uL release
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medium. Release medium was 10 mM PBS pH 7.4 with 0.1% sodium azide. A flow rate of 8
mL/min was used for the study with the cell temperature maintained at 37ºC. Release samples
were drawn at 1h, 3h, 5h, 7 hr, 12 hr, 1d, 2d, 3d, 4d, 5d, 6d, 7d and 10d. At each time point 5
mL of release solution was taken and replaced with 5 mL of fresh PBS. CDDP content in the
release solution was determined by ICP-OES. Media replacement during the release study was
considered in the calculation of cumulative release.
Another type of release study was conducted to obtain CDDP released from
nCaPCMHACDDP (drug loading 139 ug CDDP/ mg nCaPCMHA) and nCaPDCDDP (drug loading
216 ug CDDP/ mg nCaPD) specifically for use in cytotoxicity studies. In these release studies
100 uL of the nCaPxCDDP suspensions were loaded into triplicate Eppendorf tubes with 1.2 mL
sterile 0.9% saline. Samples were sonicated then placed on a heated rocker at 37ºC for 3 days,
where mixing was conducted by tumbling the tube contents. The samples were centrifuged
14000 rpm in an Eppendorf Micro Centrifuge with a 5415 C rotor (Hamburg, Germany). The
entire supernatant was collected and filtered using a 0.2 µm filter. The three samples of
nCaPxCDDP supernatant were pooled and CDDP content was measured by ICP-OES.
4.2.4 Surface Plasmon Resonance
Interaction of nCaPCMHACDDP, CMHA (~34 kDa) and HA (60 kDa) with CD44 were studied
with surface plasmon resonance, BioRad ProteOn™ XPR36 with a GLC ProteOn™ sensor chip
(BioRad, Hercules, CA). Recombinant human CD44-Fc chimera (~170 kDa) (R&D Systems,
Minneapolis, MN) was immobilized on the sensor chip using amine coupling chemistry ProteOn
Amine Coupling Kit. Briefly, the sensor chip surface was activated with 1:1 mixture of sulfo-Nhydroxysuccinimide (sulfo-NHS) and ethyl-3(3-dimethylamino)propyl carbodiimide (EDC) for 7
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min. CD44-Fc was dissolved in 10mM acetate buffer pH 4 to a concentration of 5 ug/mL and
flown over the activated surface for 14 min. The remaining reactive groups were blocked with
1M ethanolamine HCl pH 8.5. A blank flow channel (FC) was prepared by EDC/NHS activation
without the CD44 receptor. Throughout all the SPR measurements PBS pH 7.4 supplemented
with 0.005% Tween 20 was used as the running buffer. Samples were diluted with running
buffer. CMHA and HA were diluted to concentrations of 1 uM and 5 uM. . nCaPxCDDP
samples were diluted to a concentration of 350 ug/ml, which was found to be a good compromise
between sufficient binding response and bulk refractive index shift. The samples were injected
over the sensor chip surface coated with human CD44-Fc at 100 uL/min for 150 s. The
dissociation in the running buffer took place for another 600 s. Between the measurement cycles
the sensor chip surface was regenerated with 10mM glycine HCl pH 2.0 at a flow rate of 200
uL/min. The responses on the blank flow cell were subtracted from the CD44-Fc coated flow
cell.
4.2.5 Flow Cytometry
LMS, BT-474 and BT-474m cells were analyzed for CD44 and CD24 expression using flow
cytometry. NIH-373 cells were analyzed for CD44 expression alone. Cells were washed once
with phosphate-buffered saline (PBS) and then harvested with 0.05% trypsin/0.025% EDTA.
Detached cells were washed with PBS that is supplemented with 0.2% (w/v) bovine serum
albumin (BSA) (wash buffer), and resuspended in the wash buffer (106 cells/100 uL).
Combinations of fluorochrome-conjugated monoclonal antibodies obtained from BioLegend®
(San Diego, CA) reactive against human and mouse CD44 (Alexa Fluor® 647) and BD
Pharmingen™ (San Jose, CA) CD24 (PE-Cy7) or their respective isotype controls were added to
the cell suspension at concentrations recommended by the manufacturer and incubated at 4°C in
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the dark for 30 to 40 min. The labeled cells were washed in the wash buffer, then analyzed on a
MACSQuant® Analyzer, MACS Miltenyi Biotec (Auburn, CA).
4.2.6 Cellular Uptake Studies
nCaPCMHA-AF488 was made via the method described in 4.2.2, with minor modifications. Briefly,
Alexa Fluor® 488 labeled CMHA was incorporated into the CMHA solution at 6% the total
volume of CMHA used in the precipitation. Otherwise all reaction steps to create nCaPCMHA
were performed the same. BT-474m cells were seeded at a density of 1 x 105 cells in an 8-well
glass bottom plate and allowed to adhere for 24 hours. After which nCaPCMHA-AF488 was added at
the following concentrations: 200 ug/mL, 1 mg/mL, or 2 mg/mL in 500 uL complete media.
After 2, 8, and 18 h post-incubation, the glass slide chambers were washed 2x with PBS to
remove any loose nanoparticles, and the cells were fixed 4% paraformaldehyde in PBS for 15
min. The fixed cells were washed with PBS 3x to remove the excess paraformaldehyde, and then
dried for 3 h. The fixed cells were stained and mounted with Prolong® Gold anti-fade mounting
media containing the nuclear stain 4′,6-diamidino-2-phenylindole (DAPI) (Thermo Fisher
Scientific, Waltham, MA). Microscopic analysis was performed using a Nikon A1R Spectral
Confocal Microscope. Conditions of the confocal microscopic analysis were a Z-stack thickness
of 11 um, individual stack thickness of 0.35 um and an oil immersed 40x objective.
4.2.7 Cytotoxicity
Cytotoxicity experiments were conducted using NIH-3T3, LMS, BT-474 and BT-474m cells
plated in 96 well plates. at 4 x 104, 5 x 104, 6 x 104, and 2 x 105 cells/mL, respectively with 50 uL
suspension per well. NIH-3T3 and BT-474 cells were negative control cell types relative to
CD44 expression, as both cell types have CD44 negative or low expression. LMS and BT-474m
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cells were experimental cells for CD44 targeted cytotoxicity. These cell types allow for the
determination of cytotoxicity of nCaPCMHACDDP relative to CD44 expression to elucidate if
CMHA enhances cell uptake and consequently cytotoxicity. Cells were allowed to proliferate
for 24 hours following which drug was added in 50 uL volumes. The following groups were
examined: CDDP, Aq-CDDP, CMHA reacted with Aq CDDP (Aq CDDP – CMHA), D reacted
with Aq CDDP (Aq CDDP – D), CDDP released from nCaPCMHACDDP, CDDP released from
nCaPDCDDP, nCaPCMHACDDP, nCaPDCDDP, nCaPCMHA, nCaPD, CMHA and D. Each group
was serially diluted 1:3 across the plate using PBS. Cells were assayed 48 h after drug addition
using in an MTS assay (CellTiter 96® AQueous One, G3580, Promega Corp., Madison, WI),
where metabolic activity was determined using a Spectramax Plus 384 Spectrophotometer
(Molecular Biosciences, Sunnyvale, CA) at an absorbance of 490nm. To determine the IC50
(50% inhibitory concentration) a non-linear regression curve fit analysis was performed with at
least four replicates per group per concentration. All experiments shown were repeated at least
twice and often thrice.
4.2.8 BT-474m Tumor Take Rate
To assess the growth parameters of BT-474m tumors a tumor take rate study was performed.
This was performed to ensure that tumors will growth at a steady pace, without growing too fast
causing necrosis or too slow such that they regress on their own. We utilized a BD Matrigel™ to
cells in base media ratio of 60:40. Four mice were used per group. The tumor take rate study
was conducted using 8, 6-8 week old, athymic nude mice. 5 x 105 cells in a 100 uL volume were
injected subcutaneously, based on the cell number utilized for a comparable transformed breast
cancer cell type50. Animals were monitored at least every other day for normal grooming and
appearance. Tumors were measured beginning at day 7 following inoculation. At this time, the
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Matrigel has degraded from the initial 100 uL injection, allowing for a true cell-based tumor
volume measurement.
4.2.9 nCaPCMHACDDP In Vivo Maximum Tolerable Dose Determination
Two J:Nu mice carrying BT-474m tumors were injected once intratumorally with 10 mg/kg
nCaPCMHACDDP (80-90 uL per injection). A second study was conducted using athymic nude
mice, where a 7 mg/kg dose of nCaPCMHACDDP (60-70 uL) was administered once
intratumorally. For both studies animals were monitored daily for weight loss and grooming.
4.2.10 nCaPCMHACDDP In Vivo Anti-Tumor Efficacy and Toxicity Study
An efficacy and toxicity study was performed using BT-474m cells in J:Nu mice. The study
included 24, 6 week old mice inoculated with 5x105 BT-474m cells in 100μL of a 60 : 40 ratio of
BD Matrigel™ : cells in base media in the right rear flank via a 25-gauge needle. Tumors were
measured daily 7 days following inoculation using digital calipers to calculate the tumor volume
as follows: V = (W)2 * L * 0.4
Tumors were treated once with: 2.8 mg/kg (60 uL) CDDP NT (8 mice), 60 uL of saline NT (4
mice), 60 µL of nCaPCMHA NT (4 mice), 7 mg/kg nCaPCMHACDDP NT (8 mice), when tumor
volume reached 100 ± 10 mm3.
Systemic toxicity was evaluated by weight change and overall grooming/appearance.
Tumor volume and mouse weight were monitored at least every other day. Mice were euthanized
due to significant weight loss (> 15%), a tumor length measurement greater than 20 mm, or
completion of the study (day 30). All animal experimental procedures were approved by the
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Animal Care and Use Committee of the University of Connecticut Health Center, (Farmington,
CT).
4.2.11 Statistical Analysis
Statistical analysis was performed using an unpaired t-test (comparing two groups) or Tukey
one-way ANOVA (comparing three or more test groups to a control group), as indicated in the
methods. A P-value of less than 0.05 was considered statistically significant. Data is presented
as a mean value with its standard deviation indicated (mean + SD).
4.3 Results
4.3.1 Physical Characterization of nCaPCMHACDDP
A side by side comparison of nCaPCMHACDDP and nCaPDCDDP is shown in Table 4.1.
Nanoparticle yield is of great importance for scale up123. Precipitation of nCaPCMHA results in a
7x the yield of nCaPD.

The average CDDP concentration in suspension is higher for

nCaPDCDDP, as is the drug loading. nCaPCMHACDDP are statistically larger than nCaPDCDDP,
but their polydispersities are comparable. Transmission electron microscopy (TEM) (Figure 4.2)
showed that nCaPCMHACDDP and nCaPDCDDP in suspension form small aggregates that
correlate well with their measured particle size using DLS, 204 ± 13 nm and 149 ± 7 nm,
respectively. Zeta potentials of nCaPCMHACDDP and nCaPDCDDP were -43±4 mV and -35±5
mV, respectively. A zeta potential of ± 30 mV has enhanced stability as the surface change aids
in preventing aggregation74. XRD comparing the nCaPs as a wet suspension, nCaP lyophilized
and microCaP showed that both nCaPs are poorly crystalline with the major peak occurring at
30º corresponding well with hydroxyapatite (HA) while microCaP was more crystalline in nature
resembling brushite and poorly crystalline HA (Figure 4.3) 113,135.
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4.3.2 nCaPCMHACDDP In Vitro Release
The in vitro release of the nCaPCMHACDDP and nCaPDCDDP in PBS, pH 7.4, at 37° C over time
can be seen in Figure 4.4. Both formulations exhibit continuous in vitro release. A burst release
of CDDP was exhibited in the first 2 days, with slower, continuous release out to day 10. At day
2, nCaPCMHACDDP released 74% of the total CDDP available while nCaPDCDDP released 45%.
At the 7 day completion of the release study nCaP CMHACDDP released 86% of bound CDDP and
nCaPDCDDP released 74.5%. Drug was released significantly faster and more completely from
nCaPCMHACDDP than from nCaPDCDDP.
In the three day release study conducted to obtain a concentrated supernatant to assess if active
drug was released via cytotoxicity testing, nCaPCMHACDDP released 89% of the total CDDP
loaded. nCaPDCDDP released only 34% of the total CDDP available for release.

Both

supernatants containing released drug were stored and used for direct comparison to the same
batch of intact nCaPCMHACDDP and nCaPDCDDP in cytotoxicity studies.
4.3.3 Surface Plasmon Resonance
To assess the interaction and binding of CMHA and nCaPCMHACDDP to CD44, SPR was
performed. Human CD44 chimera was immobilized on the sensor chip to determine the binding
of HA, CMHA, nCaPCMHACDDP. To correct for bulk shift due to size of the nanoparticles,
nCaPDCDDP was examined as a control. As expected the HA most effectively bound CD44 with
CMHA nearing the binding affinity of HA but not matching it (Figure 4.5). nCaP CMHACDDP
also binds CD44, but this binding is lower than free CMHA or HA. Importantly, this binding is
specific as it overcomes any bulk interactions observed with nCaPDCDDP.
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4.3.4 Flow Cytometry
Flow cytometry analysis of NIH-3T3 cells revealed that they minimally express CD44, at 8.94%
of the population after isotype control subtraction (Figure 4.6). We did not examine these cells
for CD24, as they are mouse fibroblasts and their expression of CD24 is not important for this
study. LMS cells which are transformed human mammary cancer cells, were analyzed for CD24
and CD44 expression, finding they stained 97.3% positive for CD44 and negative for CD24
(Figure 4.7 C). Importantly, this phenotype is associated with the breast CSC phenotype52. BT474 stained 1.71% positive for both CD44 and CD24, but the majority of cells stained positively
for CD24 alone, 98.3% (Figure 4.8 C) BT-474m cells stained 99.7% positive for CD44 and
negative for CD24, comparable to profile of the LMS cells, CD44+/CD24-/low.
4.3.5 Cellular Uptake Studies
In this cell uptake experiment, BT-474m cells were used as they have high CD44 expression.
Cells were administered varying doses of nCaPCMHA-AF488 at 200 ug/mL, 1 mg/mL, or 2 mg/mL.
Cells were imaged at 2, 8, and 18 h of incubation following washing to remove any free
nanoparticles. No significant uptake was found for the 200 ug/mL or 1 mg/mL concentrations at
any time tested (images not shown). At the 2 mg/mL dose, significant cellular uptake was found
at 18 hours post treatment. These results are shown in Figure 4.9 A-D. Z-stack images were
obtained, confirming the nCaPCMHA-AF488 was within the cell with nuclei counterstained with
DAPI.
4.3.6 Cytotoxicity Evaluation of nCaPCMHACDDP and nCaPDCDDP
NIH-3T3 (CD44low) and LMS (CD44+/CD24-) cells were used to study the cytotoxicity of:
CDDP, Aq-CDDP, CMHA reacted with Aq CDDP (Aq CDDP – CMHA), D reacted with Aq
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CDDP (Aq CDDP – D), CDDP released from nCaPCMHACDDP (nCaPCMHACDDP (R)), CDDP
released from nCaPDCDDP (nCaPDCDDP (R)), nCaPCMHACDDP, nCaPDCDDP, CMHA and D.
CMHA is not cytotoxic (Figure 4.9 A). Darvan alone caused some toxicity at a top dose of 1
mg/mL (Figure 4.9 B). Non-linear regression curve fit analysis was performed for each of these
treatments and the resulting IC50 values are shown in Figure 4.9 C. Both CDDP released from
nCaPCMHACDDP and nCaPDCDDP have comparable cytotoxicity to CDDP alone. D reacted with
Aq CDDP inhibits the cytotoxicity of Aq CDDP, this interaction also inhibits the cytotoxicity of
nCaPDCDDP (P < 0.05).
LMS cells were analyzed against the same groups as the NIH-3T3 cells. CMHA has no
cytotoxicity to LMS cells (Figure 4.10 A). D has some cytotoxicity at the top dose administered,
1 mg/mL (Figure 4.10 B). The calculated IC50 values are shown in Figure 4.10 C. CDDP
released from nCaPCMHACDDP has comparable cytotoxicity to CDDP.

Both nanoparticle

formulations were significantly less cytotoxic than CDDP (P < 0.05).
BT-474 (CD44-/low/CD24+) and BT-474m (CD44+/CD24-/low) cells were examined in
cytotoxicity tests against: CDDP, Aq-CDDP, CMHA reacted with Aq CDDP (Aq CDDP –
CMHA), D reacted with Aq CDDP (Aq CDDP – D), nCaPCMHACDDP and nCaPDCDDP. The
calculated IC50 values for each group with BT-474 cells are shown in Figure 4.11 A. Overall, a
similar trend was found against BT-474 cells as those previously tested with one important
exception; nCaPCMHACDDP was significantly more cytotoxic than CDDP against BT-474 cells(P
< 0.05).

Against BT-474m cells the calculated IC50 values are shown in Figure 4.11 B.

Importantly, nCaPCMHACDDP was as cytotoxic as free CDDP. nCaPDCDDP and D reacted with
Aq CDDP were significantly less cytotoxic than CDDP (P < 0.05).
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Upon a routine mycoplasma test, it was determined that our BT-474 and BT-474m cells
were positive for mycoplasma (MycoAlert™ Mycoplasma Detection Kit, Lonza Group Ltd.,
Basel, Switzerland). Mycoplasma is a very common cell culture contamination that affects
laboratories worldwide. It is estimated that ATCC, National Cancer Institute and the FDA have
an average mycoplasma contamination rate in cell culture of 13.5%151. This rate is expected to
be higher at academic institutions, due to a lack of testing for mycoplasma and reliance of
antibiotics. In cell culture a mycoplasma can outnumber the cells by 1000:1, competing for
nutrients causing changes in cell growth and protein production152. Due to this, a commercial
mycoplasma removal kit was purchased and used on the BT-474 and BT-474m cells
(MycoZap™ Elimination Reagent, Lonza). After treatment both cell types tested negative for
mycoplasma and thus all of the studies were repeated using mycoplasma free cells.
Flow cytometry was repeated on the BT-474m cells after mycoplasma removal to ensure
their expression of CD44 remained high. The CD44+/CD24-/low phenotype remained after
mycoplasma removal, Figure 4.12 C. BT-474 cells normally have a CD44-/low/CD24+ therefore it
expected that their phenotype would change in the presence of mycoplasma51,153. All of the
cytotoxicity tests performed prior to mycoplasma testing were repeated three times following
mycoplasma removal. Data shown represents one test, but the trend remains the same from
experiment to experiment. The cytotoxicity of each stabilizer and the resulting nanoparticles
were examined against BT-474 and BT-474m cells (Figure 4.13 A-D). CMHA does not have
any inherent toxicity to either cell type (Figure 4.13 A). Darvan caused 50% cell death at its top
concentration of 1 mg/mL. with BT-474m cells (Figure 4.13 B).

Neither nanoparticle

formulations were cytotoxic at concentrations tested which match the nCaP in nCaPxCDDP test
groups (Figure 4.13 C & D).
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The cytotoxicity of CDDP, Aq CDDP, Aq CDDP reacted with CMHA (Aq CDDP –
CMHA), Aq CDDP reacted with D (Aq CDDP – D), nCaPCMHACDDP and nCaPDCDDP were
re-examined against BT-474 and BT-474m cells. The curve fits are shown in Figure 4.14 A-F for
BT-474 cells. The IC50 values calculated from these curve fits are shown in Figure 4.15.
nCaPCMHACDDP remained significantly more cytotoxic than CDDP alone, as did Aq CDDP (P <
0.0001). Additionally, nCaPDCDDP was the most cytotoxic, which was not found in experiments
with cells infected with mycoplasma. The curve fits for each group tested against BT-474m cells
are shown in Figure 4.16 A-F. The IC50 values calculated from these curves are shown in
Figure 4.17. Here there were no significant differences between groups tested compared to
CDDP, with the exception of Aq CDDP – D, which was very significantly less cytotoxic (P <
0.0001).
4.3.7 BT-474m Tumor Take Rate
Two tumor take rate studies were conducted with BT-474m cells. Athymic nude mice were
injected with 5 x 105 BT-474m cells per injection in 100 uL of BD Matrigel™ :cells in base
media at a ratio of 60:40 subcutaneously. Seven days following cell inoculation, tumors were
palpable and the Matrigel plug had visibly degraded from the time of injection. At this time
tumors were quite small, 50 mm3 on average. After approximately 12 days tumors were 100 mm3
on average (Figure 4.18 A). Animals were monitored for 25 days following inoculation where
tumors continued to grow steadily up to 500 mm3 without necrosis.
4.3.8 nCaPCMHACDDP Maximum Tolerable Dose
A maximum tolerable dose study was conducted first in two 6-8 week old, J:Nu mice bearing
BT-474m tumors at 150 mm3, where each animal received nCaPCMHACDDP at 10 mg/kg (80-90
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uL) intratumorally. Four days following treatment one mouse lost more than 15% of its weight
at the time of treatment. The other mouse lost only 6.7% of its weight at treatment and fully
recovered. The second MTD study was conducted using 6-8 week old, athymic nude mice
bearing BT-474m tumors. Animals were treated at an average tumor volume of 170 mm3, 14
days following cell inoculation. Four animals were treated with 7 mg/kg nCaP CMHACDDP (6070 uL) intratumorally. Four additional animals were monitored as untreated controls. The results
are shown in Figure 4.18 B, where a maximum weight loss was 5%, two to five days following
treatment. This is an acceptable weight loss during treatment with chemotherapeutics, therefore
this dose was deemed tolerable.
4.3.9 In Vivo Anti-Tumor Efficacy and Toxicity Study
The in vivo anti-tumor efficacy of the nCaPCMHACDDP was evaluated using BT-474m human
xenograft tumors in 6 week old J:Nu mice. Mice were injected with 5x105 BT-474m cells in 100
µL of 60% Matrigel™ 60% cells in base media subcutaneously. Tumors were treated once with:
2.8 mg/kg (60 uL) CDDP NT (8 mice), 60 uL of saline NT (4 mice), 60 µL of nCaP CMHA NT (4
mice), 7 mg/kg nCaPCMHACDDP NT (8 mice), when tumor volume reached 100 ± 10 mm3. The
change in tumor volume and mouse weight was evaluated for 30 days post treatment (Figure
4.19). No animal experience weight loss greater than 2% (data not shown). Near tumor delivery
of 2.8 mg/kg CDDP was most effective at inhibiting tumor growth. No treatment caused toxicity
to the animals as measured by weight loss and overall grooming/appearance. Survival over time
post treatment was evaluated for each group. The results are shown in Figure 4.20.
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4.4 Discussion
The addition of CMHA during precipitation of CaP resulted in successful stabilization of nCaP.
TEM images reveal small 30-80 nm particles, agglomerated into larger particles, which likely
accounts for the 200 nm size measured by DLS. The introduction of D or CMHA clearly
restricts the crystallization of CaP, as can be seen by the broad peaks of nCaP XRD spectra.
MicroCaP created by precipitation without the addition of stabilizer exhibits a crystalline pattern
with major peaks comparable to brushite, (calcium hydrogen phosphate dehydrate, CaHPO4·
2H2O). This form of calcium phosphate naturally occurs and dissolves in the body as kidney
stones and is therefore highly biocompatible135. The particle sizes obtained here made for a
readily injectable nanoparticle suspension via a 25G needle.
It was shown in previous studies and Chapter 2, that D halts CaP crystal growth16. This
is believed to be due in part to the repeating carboxylate groups throughout the polymer. There
is significant literature showing the carboxylate groups of sodium citrate (3 carboxylate groups
per molecule) interact with the Ca ions during CaP precipitation acting as a surfactant to halt
nucleation134,154–157. The interaction of D and CaP created regularly shaped nCaP, with low
polydispersity. This was also true for citrate. Unfortunately, these stabilizers inhibited the
cytotoxicity of CDDP. Interestingly, it was recently shown that citrate nearly irreversibly binds
CDDP and renders it unable to intercalate with DNA, making it biologically inactive158. This
finding complements our findings in Chapter 3. Thus, a balance needs to be achieved between
stable nCaP and their effective binding and release of biologically active CDDP. The findings of
Chapters 2 & 3 led us to the utilization of a stabilizer that has biological targeting capability
concurrent with nCaP stabilization. Here the approach was to use CMHA to enhance uptake of
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nCaPCMHACDDP by cells expressing CD44. CMHA is HA with additional carboxylate groups,
but in comparison to D and citrate there are fewer carboxylate groups per molecular weight.
To date, there is not a compendial in vitro release test for parenteral dosage forms. The
current USP apparatus are specified to test release/dissolution of oral and transdermal dosage
forms. As the development of liposomes and nanoparticles advances towards a commercial
product, there is a desperate need to evaluate batch to batch quality by developing an in vitro
release method that can discriminate between small variations in formulation. Published in vitro
release testing methods for controlled release nanoparticles/liposomes include, flow through22,
dialysis sac119,124,159, or sample and separate15,16. Major drawbacks exist for sample and separate
as well as dialysis sac methods. Sample and separate methods involve the use of centrifugation
and/or filtration where the liposomes can be disrupted causing erroneous release, additionally
great variability exists from lab to lab with vessel size, agitation and centrifugation making the
test not reproducible. Dialysis methods are limited by insufficient agitation within the dialysis
sac, delayed diffusion of released drug through the dialysis membrane and high concentration of
carrier within the sac limiting release120,121.

Dr. Diane Burgess’ lab at the University of

Connecticut, has been working towards the development of a compendial release testing
method/system to fill the current void for nanoparticle formulations. They developed a dialysis
adapter to fit within the standard sample cell in the Sotax™ CE7 USP apparatus 4, where the
dialysis membrane MWCO is chosen such that when the drug of interest releases, it can freely
flow through the dialysis membrane and the carrier (liposome or nanoparticle) stays within the
dialysis adapter22. They were able to discriminate between different liposomal formulations
using the dialysis adapter modified USP 4 apparatus. Here we compared the in vitro release of
CDDP from nCaPCMHACDDP and nCaPDCDDP. In a side-by-side release test, nCaPCMHACDDP
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released 73% of the CDDP bound compared to 45% from nCaPDCDDP in 2 days. As release
continued, nCaPCMHACDDP released a total of 86% while nCaPDCDDP released 74.5%. Several
papers have published the use of HA to create particles containing CDDP via ion complexes
between the carboxylate groups of HA to aquated species of CDDP160–162. In each study it was
shown that Aq CDDP that had been complexed with HA could subsequently be released both in
vitro and in vivo. Release was enhanced in the presence of Cl- ions160. This taken together with
the cytotoxicity examinations of each stabilizer reacted with Aq CDDP may explain the
enhanced release of CDDP from nCaPCMHACDDP over nCaPDCDDP, where the interaction
between Aq CDDP and CMHA is weaker than with D.
SPR analysis of targeted nanoparticles is challenging. SPR systems utilize expensive
microfluidics that normally transport solutions containing ligands or proteins of interest, but
generally not solid materials such as nCaP particles. Of additional concern is the ability to
correct for bulk response due to the relatively large nanoparticles passing over the sensor. Here
we were able to use nCaPDCDDP as a comparably sized, non-specific nanoparticle control. The
density of receptor (here CD44) immobilized on the chip is inherently related to the response
measured, therefore we utilized a low density of CD44 on the chip surface163. After correcting
for bulk nanoparticle response, it is clear that nCaPCMHACDDP does effectively bind CD44. The
highest binding observed was for HA (60 kDa), followed by CMHA (34 kDa) alone. The
chemical modification of HA to create CMHA occurs at 15 – 20% of the repeating 6’-OH groups
of the N-acetylglucosamine residues. The interaction of CD44 and HA has low affinity but high
avidity. A single HA disaccharide contains an N-acetyl-D-glucosamine and D-glucuronic acid,
HA2. It has been shown that HA6 is necessary for binding CD44, but HA10 is more preferential164.
Additionally, divalent binding occurs with HA20 and larger oligomers. This likely explains the
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slight reduction in binding of CMHA to CD44, due to an interruption of sugar residues by the
added carboxylate groups of CMHA compared to HA. This may also explain the significant
time required for cellular uptake of nCaPCMHA-AF488, where uptake was only found significantly
at 18 hours post treatment.

This was a preliminary test of cellular uptake.

These were

insufficient to prove that nCaPCMHA-AF488 cellular uptake was mediated by CD44. To do so, at
least two controls are necessary, a CD44- cell type and a CD44+ cell type pre-treated with HA to
effectively saturate the CD44 receptors. nCaPCMHACDDP showed lower binding than CMHA,
which is believed to be due to two factors. By utilizing fluorescently labeled CMHA, we were
able to determine that during precipitation of nCaPCMHA only 30% of the available CMHA is
incorporated. Additionally, nCaPCMHACDDP is stored as a suspension which allows the CaP to
undergo Ostwald ripening which could further trap the CMHA within the nCaP core93,165.
Interestingly, nCaPCMHACDDP did not show preferential toxicity to cells with high CD44
expression (LMS and BT-474m) compared to those with low or negative CD44 expression
(NIH-3T3 and BT-474). It was hypothesized that the CMHA would allow for preferential
cytotoxicity to cells with high CD44 expression due to the targeting of CD44 via CMHA. It was
expected that the BT-474m and LMS cells would be chemotherapy resistant, as it was shown that
LMS cells were resistant to other chemotherapies (docetaxel and tamoxifen)

17,50

. When treated

with CDDP alone, both BT-474m and LMS cells were relatively sensitive to CDDP. This is
likely explained by the nature of CDDP toxicity, where it intercalates with DNA, causing DNA
adducts that cannot be removed by DNA repair machinery prior to replication resulting in cell
death. LMS and BT-474m cells divide at 2-3x the rate of their non-transformed counter-parts,
MCF-7 and BT-474 cells, respectively.

Importantly, nCaPCMHACDDP was as cytotoxic as

CDDP alone against all cell types tested. This finding is not common for targeted nanoparticles
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utilizing HA and may be due in part to released CDDP from the formulation. The controlled
release of CDDP from nCaPCMHACDDP allowed for prolonged delivery of drug to the slower
replicating BT-474 cells, which could explain the enhanced cytotoxicity of nCaPCMHACDDP
over CDDP alone. HA bioconjugates with Taxol were less cytotoxic than free Taxol against
cells expressing CD44 and had limited to no cytotoxicity against cells that did not express
CD44166,167. Mesoporous silica nanoparticles targeted with HA carrying doxorubicin, were
significantly more cytotoxic than doxorubicin alone against CD44 expressing cells, but were
significantly less cytotoxic to CD44 negative cells168. This can be explained by specific CD44
mediated uptake that allowed drug to release intracellularly, where cells lacking CD44 did not
take up the particles. nCaPCMHACDDP may not be as readily taken up as nanoparticles with HA
on their surface, due to limited CMHA on the surface and the chemical modifications on HA to
make CMHA.
This study was the first to create BT-474m cell based tumors in nude mice. BT-474m
cells were developed following a previously reported method for transformation of human
epithelial breast cancer cells, in the same lab at UCHC50. Within that research an animal model
was developed, where 5 x 105 cells were injected orthotopically into athymic nude mice using
Matrigel, where tumor volume reached 600 mm3, 20 days following inoculation. Here, we also
used 5 x 105 cells, but cells were injected subcutaneously in the flank of J:Nu mice. The BT474m tumors created here showed high variability in tumor volume in the control groups as well
as the treated groups. Due to the high variability in tumor volume, significant differences did not
exist between treatment groups. From our experience with the FaDu tumor model in Chapter 3
of this dissertation, we found that 2 x 105 and 8 x 105 FaDu cells were insufficient for significant
tumor growth beyond inoculation volume and 2 x 106 was sufficient with limited differences in
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tumor volume from the 5 x 106 cell number inoculation. If we injected a higher number of BT474m cells we may have found limited variability in tumor volume, because sufficient cells were
injected such that all tumors grew beyond their inoculation volume.
Levy-Nissenbaum et al. recently showed that a local dose of polymer carrying CDDP
administered near or surrounding the tumor significantly increased the anti-tumor efficacy
compared to an intratumoral injection169. Tumor tissue is very dense with high interstitial fluid
pressure82 and therefore we have had difficulty administering even very small (60 uL) volumes
directly into the tumor. These complications taken together with the results of Levy-Nissenbaum
led us to change to a near tumor administration of treatment. To do so, the skin above each
tumor was gently lifted away from the tumor surface and with a single injection drug was
deposited on either side of the tumor. For some animals this was easy to achieve and others, this
proved more difficult as the skin would not lift from the tumor surface. As this was our first
attempt at near tumor treatment, we are unsure if this complication has any impact on the
standard deviations within each treatment group.

At the time of resection, depots of

nCaPCMHACDDP were found. Animals with the largest tumor volumes had nCaPCMHACDDP
located on just one side of the tumor, while animals with smaller tumor volumes had depots on
opposing sides of the tumor. We believe the lack of even distribution nCaPCMHACDDP may
have contributed to lack of anti-tumor efficacy observed in these animals. nCaPCMHACDDP does
not freely diffuse throughout the tumor due to the density of the tumor and therefore only the
areas of the tumor proximal to the nCaPCMHACDDP depot are treated with CDDP. The overall
goal of this treatment modality is to cover more of the tumor area with drug, therefore if the drug
deposited on just one side of the tumor, potentially fewer cancer cells we treated. Taken together
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it is likely that, the ability of free CDDP to diffuse throughout the tumor enabled the tumor
growth inhibition observed in the CDDP alone group.
4.5 Conclusions
CMHA is a novel and effective stabilizer for nCaP that can bind CD44 for potential targeting
applications. Importantly, we determined that CMHA has no negative impact of the biological
activity of CDDP in vitro, against human breast cancer cells. nCaPCMHACDDP allowed for
efficient release of CDDP in neutral PBS which should be enhanced by CaP dissolution in lower
pH environments, like that found in solid tumors. nCaPCMHACDDP had equivalent cytotoxicity
to CDDP alone against both CD44+ and CD44- cells. Tumors are very heterogeneous in cell
surface expression and therefore non-exclusive cytotoxicity is important in vivo. Our in vivo
efficacy study showed that near tumor delivery of 2.8 mg/kg CDDP was most effective at
inhibiting tumor growth. This finding agrees with a recently published clinical trial showing
neoadjuvant CDDP treatment was effective for patients with TNBC, though this treatment has
not yet been adopted clinically. Here we locally administered less than a third of the typical
systemic dose of CDDP for a mouse and found excellent tumor growth delay. Importantly, a
higher dose of nCaPCMHACDDP should be examined in vivo to evaluate the targeting of therapy
resistant CD44+ cells, which should increase the efficacy of locally delivered CDDP.
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Figure 4.1 Chemical modification of hyaluronic acid (HA) to synthesize carboxymethyl
hyaluronic acid (CMHA).

Table 4.1 Side by side comparison of nCaPCMHACDDP and nCaPDCDDP batch characteristics.
Ratio of components, precipitation volume, and stabilizer final concentration remain the same
from batch to batch. Yield, CDDP concentration, drug loading, particle size and polydispersity
represent averages and standard deviations from a minimum of three batches.
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Figure 4.2 TEM images of (A) nCaPCMHACDDP and (B) nCaPDCDDP, depicting small nCaP
20-50 nm agglomerated into larger groups of particles.
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Figure 4.3 XRD spectra of (A) nCaPCMHA suspension (nCaPCMHA wet), lyophilized nCaPCMHA
(nCaPCMHA dry) and lyophilized CaP without stabilizer added during precipitation (microCaP
dry) (B) nCaPD suspension (nCaPD wet), lyophilized nCaPD (nCaPD dry) and lyophilized CaP
without stabilizer added during precipitation (microCaP dry). Both plots show hydroxyapatite
standard (JCPDS, #09-0432) (bars) for comparison. MicroCaP pattern has major peaks
characteristic of Brushite (peaks denoted with open circles). MicroCaP was precipitated without
a stabilizer and is crystalline. With a stabilizer present (CMHA or D) the crystallization is halted,
depicted by broad peaks showing no long range crystal order.
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Figure 4.4 In vitro release testing using a modified USP Apparatus 4 (dialysis adapter molecular
weight cut off 100 kDa) of nCaPCMHACDDP and nCaPDCDDP. Cumulative CDDP released is
plotted using the left y-axis, percent CDDP released using right y-axis. Both formulations
provide sustained delivery of CDDP for 2 days. After 2 days nCaPCMHACDDP released 74% of
bound CDDP available for release and release plateaus. nCaPDCDDP released 45% of bound
CDDP in 2 days. At study completion, nCaPCMHACDDP released more CDDP faster than
nCaPDCDDP with total percent release at 86% and 74%, respectively. Release in 10 mM PBS
pH 7.4, 0.1% sodium azide at 37ºC.
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Figure 4.5 Surface plasmon resonance sensogram depicting binding of CMHA, HA and
nCaPCMHACDDP with immobilized CD44. All data shown has been corrected for non-specific
binding to blank channels of blocked NHS-EDC. nCaPDCDDP was used as a comparable sized
control, which does not have specific interactions with CD44. HA has the highest affinity for
CD44, followed by CMHA then nCaPCMHACDDP.
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Figure 4.6 Flow cytometry data shows NIH-3T3 cells are CD44-/low. These cells will serve as a
negative control for CD44 targeting, as they have low CD44 expression. (A) Unstained control
(B) isotype control (C) stained cells with CD44 – Alexa Fluor® 647 against forward scattered
light (FSC, proportional to cell surface area).

Figure 4.7 Flow cytometry data confirms that LMS cells are CD24-/low/CD44high. These cells will
be the experimental group for CD44 targeting, as they have high CD44 expression. (A)
Unstained control (B) isotype control (C) stained cells with CD44 – Alexa Fluor® 647 and
CD24 – PE-Cy7.
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Figure 4.8 Flow cytometry data demonstrates that BT-474 cells are CD24high/CD44low. These
cells will serve as the negative control for CD44 targeting, because they lack CD44 expression.
(A) Unstained control, (B) isotype control, (C) stained cells with CD44 – Alexa Fluor® 647 and
CD24 – PE-Cy7. BT-474m cells are CD24low/CD44high. These cells will serve as the
experimental group to investigate CD44 targeting, as they have high CD44 expression. (D)
Unstained control, (E) isotype control, (F) stained cells with CD44 – Alexa Fluor® 647 and
CD24 – PE-Cy7.
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Figure 4.9 Cellular uptake study using BT-474m cells. Cells were plated and allowed to adhere
for 24 hours, after which nCaPCMHA-AF488 was added at a concentration of 2 mg/mL, in complete
media. After 18 hours, nCaPCMHA-AF488 can clearly be seen within cells as confirmed by z-stack
images. (A) Cells stained with DAPI, (B) Cells imaged containing nCaPCMHA-AF488, (C) Overlay
of DAPI and AF488 images, showing nCaPCMHA-AF488 uptake, and (D) Differential interference
contrast (DIC) image.

113

Jessica Lea Woodman – University of Connecticut, 2014

Figure 4.10 Mouse fibroblast cells, NIH-3T3, were used to examine the in vitro cytotoxicity of
CMHA and D. (A) CMHA has no toxicity at a top concentration of 1 mg/mL. (B) D causes 50%
cell death at a top concentration of 1 mg/mL. (C) Calculated IC50 values of: CDDP, Aq CDDP,
CDDP released from nCaPCMHACDDP, CDDP released from nCaPDCDDP, nCaPCMHACDDP,
nCaPDCDDP, Aq CDDP reacted with CMHA, and Aq CDDP reacted with D. Drug released
from nCaPCMHACDDP has the same cytotoxicity as free CDDP and Aq CDDP. (One way
ANOVA with Dunnet post-test, P < 0.05). Reacting D with Aq CDDP, significantly decreases
the cytotoxicity of Aq CDDP. Reacting CMHA with Aq CDDP does not inhibit the cytotoxicity
of Aq CDDP.
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Figure 4.11 Cytotoxicity testing results in LMS cells. (A) CMHA has no toxicity at a top
concentration of 1 mg/mL. (B) D causes 75% cell death at a top concentration of 1 mg/mL. (C)
Calculated IC50 values of: CDDP, Aq CDDP, CDDP released from nCaPCMHACDDP, CDDP
released from nCaPDCDDP, nCaPCMHACDDP, nCaPDCDDP, Aq CDDP reacted with CMHA,
and Aq CDDP reacted with D.. Drug released from nCaPCMHACDDP has the same cytotoxicity as
free CDDP and Aq CDDP. nCaPCMHACDDP was significantly less cytotoxic than CDDP
(P<0.05). nCaPDCDDP and reacting D with Aq CDDP, are significantly less cytotoxic than
CDDP (P≤0.001). Reacting CMHA with Aq CDDP does not inhibit the cytotoxicity of Aq
CDDP.
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Figure 4.12 Cytotoxicity experiments were conducted using BT-474 (CD44-) and BT-474m
(CD44+) cells. (A) Against BT-474 cells nCaPCMHACDDP is significantly more cytotoxic than
CDDP (P≤0.01). nCaPDCDDP and reacting D with Aq CDDP, are significantly less cytotoxic
than CDDP (P≤0.0001). Reacting CMHA with Aq CDDP does not inhibit the cytotoxicity of Aq
CDDP.

(B) Against BT-474m cells nCaPDCDDP and reacting D with Aq CDDP, are

significantly less cytotoxic than CDDP (P≤0.0001). Reacting CMHA with Aq CDDP does not
inhibit the cytotoxicity of Aq CDDP.
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Figure 4.13 Flow cytometry data reveals BT 474m cells remain CD24-/low/CD44high after
mycoplasma removal. This ensured that the CD44 high status was maintained after mycoplasma
removal. (A) Unstained control, (B) isotype controls, (C) stained cells with CD44 – Alexa
Fluor® 647 and CD24 – PE-Cy7.
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Figure 4.14 Cytotoxicity evaluations of nanoparticle components using BT-474 and BT-474m
cells. (A) CMHA is not cytotoxic to either cell type. (B) D is cytotoxic to BT-474m cells at a top
concentration of 1 mg/mL (C) nCaPCMHA is not cytotoxic, arrow indicates approximate
nCaPCMHA concentration in IC50 of nCaPCMHACDDP. (D) nCaPD is not cytotoxic, arrow
indicates approximate nCaPD concentration in IC50 of nCaPCMHACDDP.
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Figure 4.15 Cytotoxicity evaluation using BT-474 (CD44-) cells in an MTS assay. (A) CDDP,
(B) Aq CDDP, (C) Aq CDDP reacted with CMHA, (D) Aq CDDP reacted with D, (E)
nCaPCMHACDDP, and (F) nCaPDCDDP.
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Figure 4.16 Calculated IC50 values against BT-474 (CD44-) cells, from curves shown in Figure
4.14. nCaPCMHACDDP is significantly more cytotoxic than CDDP (P ≤ 0.0001). Reacting D with
Aq CDDP (AQ CDDP D) is significantly less cytotoxic than CDDP (P ≤ 0.0001). Reacting
CMHA with Aq CDDP (AQ CDDP CMHA) does not inhibit the cytotoxicity of Aq CDDP. Aq
CDDP is significantly more cytotoxic than CDDP (P ≤ 0.0001).
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Figure 4.17 Cytotoxicity evaluation using BT-474m (CD44+) cells in an MTS assay. (A)
CDDP, (B) Aq CDDP, (C) Aq CDDP reacted with CMHA, (D) Aq CDDP reacted with D, (E)
nCaPCMHACDDP, and (F) nCaPDCDDP.
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Figure 4.18 Calculated IC50 values against BT-474m (CD44+) cells, from curves shown in
Figure 4.16. Reacting D with Aq CDDP (AQ CDDP D) is significantly less cytotoxic than
CDDP (P ≤ 0.0001). No other groups were significantly different from CDDP.
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Figure 4.19 (A) Tumor take rate study performed in Athymic nude mice with 5 x 105 BT-474m
cells injected subcutaneously in right rear flank of animals. Data represents average tumor
volume vs days following inoculation with standard deviations. (B) Maximum tolerable dose
study conducted with Athymic nude mice (6-8 weeks old) carrying BT-474m tumors. An
intratumoral 7 mg/kg dose of nCaPCMHACDDP (4 mice/group) was compared to an untreated
control (4 mice/group). nCaPCMHACDDP caused minimal weight loss at 7 mg/kg and all animals
recovered.
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Figure 4.20 Efficacy study of nCaPCMHACDDP was conducted on J:Nu mice bearing BT-474m
tumors. Animals were treated once when their tumor volume reached 100 ± 10 mm3 and were
compared to 2.8 mg/kg CDDP administered near the tumor. Tumor volume, grooming and
weight loss were monitored every other day following treatment. The graph depicts average
tumor volume (mm3) per group versus days post treatment. The negative control Saline IT (70
uL) had no effect on tumor growth. nCaPCMHA (60 uL) had no effect on tumor growth. CDDP at
2.8 mg/kg administered near the tumor delayed tumor growth.
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Figure 4.21 Tumor weight at the end of the study or at time of euthanasia for the efficacy study
shown in Figure 4.19. The study was conducted on J:Nu mice bearing BT-474m tumors.
Animals were treated once when their tumor volume reached 100 ± 10 mm3. Tumors were
resected at the end of the study and weighed. Animals were euthanized if tumor diameter was
measured > 2 cm or at the completion of the study (Day 30). No significant differences were
found between groups.
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Figure 4.22 Survival was plotted for the efficacy study shown in Figure 4.19. The study was
conducted on J:Nu mice bearing BT-474m tumors. Animals were treated once when their tumor
volume reached 100 ± 10 mm3 and compared to 2.8 mg/kg CDDP administered near tumor (NT).
Tumor volume, grooming and weight loss were monitored every other day following treatment.
Survival was defined as a tumor diameter > 2 mm or inability to groom. A treatment of 7 mg/kg
nCaPCMHACDDP and

2.8 mg/kg CDDP (NT) were most effective at prolonging survival

compared to control treatments of Saline or nCaPCMHA (NT).
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Chapter 5
Suggested Future Directions and Conclusions
The goal of these studies was to develop a stabilized, injectable calcium phosphate
nanoparticle system for the delivery of CDDP that releases biologically active drug and can
furthermore be targeted to therapy resistant cancer cells.

Using a systematic approach to

understand the nano-molecular interactions of the stabilizer/drug/nanoparticle system and its
resulting biological effect, we have revealed pitfalls in stabilizer-drug interactions that were
previously unknown. These complex and inherently important interactions are crucial to define
in order to develop an effective drug delivery system. By studying the interaction of each
material component with the chemotherapy drug, cancer cells, and tumors, we identified a novel
stabilizer for nCaP that has biological targeting capacity and importantly does not negatively
impact the biological efficacy of CDDP. Sodium polyacrylate and sodium citrate were excellent
stabilizers for nCaP, but negatively impacted the biological activity of CDDP. It is essential in
future work to examine the components of each nanoparticle system as they interact with the
drug to be delivered as it relates to anticipated biological effect.

This process is not

commonplace for current nanoparticle research and should be adopted to prevent complications
moving forward.
This work highlighted a novel nCaP stabilizer candidate, carboxymethyl hyaluronic acid
(CMHA). We showed that nCaPCMHACDDP does bind to CD44, but this binding was much
lower than that of CMHA alone, which was lower than HA. The chemical modification of HA to
create CMHA may contribute to the lower binding of CMHA with CD44. Additionally, the
molecular weight of HA has been shown to significantly impact its binding with CD44, where
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higher molecular weights have greater binding170. The CMHA used in these studies was ~34
kDa, compared to HA at 60 kDa during SPR experiments. This is a major factor that likely
contributes to the enhanced binding of HA over CMHA observed. The incorporation of CMHA
into nCaPCMHA likely lessens the number of available CD44 binding sites as well as the
presentation of the molecule to CD44. With further funding, it would be of interest to study
varied molecular weights of CMHA, to see if higher molecular weights have increased CD44
binding similar to HA. A higher molecular weight CMHA will likely change the stabilization of
nCaPCMHA, therefore a balance must be achieved between physical and biological properties of
the resulting nanoparticle system.
More research is necessary to understand the interactions of nCaPCMHACDDP and CD44
expressed on the surface of cancer cells. The preliminary cell uptake study conducted here was
able to show uptake of nCaPCMHA-AF488 by CD44 positive BT-474m cells, but this is not
sufficient to prove uptake was mediated by CD44. To do so, thorough cellular uptake studies
combined with CD44 inhibition or saturation, via pretreatment with HA is necessary171. An
additional control would be to examine nCaPCMHA uptake by cells that do not express CD44, like
BT-474 cells. nCaPCMHACDDP had equivalent cytotoxicity in both CD44- and CD44+ cells
which is an excellent property for treating tumors in vivo, due to heterogeneity. This may be due
to sufficient drug release from nCaPCMHACDDP or possibly cellular uptake is being mediated by
a mechanism other than CD44 mediated uptake.
Each nCaPxCDDP system that was synthesized was examined in an animal anti-cancer
efficacy model. Each model utilized a different cell type to create tumors. We examined murine
head and neck cancer (HNC), human head and neck cancer and human breast cancer, in order to
demonstrate a broad range of activity. As a hypothesized negative control, we included a group
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in each study that received an intratumoral injection of CDDP alone at the maximum tolerated
volume. This was compared to an experimental group of an intratumoral dose of nCaPxCDDP at
the same volume, which delivered a significantly higher dose of CDDP, due to the high drug
loading capacity of nCaP. In four out of five animal studies, local delivery of CDDP without
nanoparticles was the most effective at delaying tumor growth. In Chapter 3, we utilized human
HNC (FaDu) cells in a subcutaneous tumor model and found that a 1.4 mg/kg intratumoral dose
of CDDP was sufficient to cause significant tumor growth delay. In that study, all animals in the
CDDP IT treatment group survived the full length of the study, 30 days. This finding is
completely novel and to our knowledge nothing comparable has been published. The efficacy of
this treatment is likely due to the ability of CDDP to diffuse freely into the tumor with local
administration. Each nCaPxCDDP IT or NT treatment did not evenly distribute throughout the
tumor as hypothesized.

This was evident in the work performed in Chapter 4 with

nCaPCMHACDDP. Tumors were resected at the time of euthanasia and those animals treated near
tumor with nCaPCMHACDDP had obvious deposits of nanoparticles. Interestingly, tumors were
smaller when two deposits of nCaPCMHACDDP were present versus larger tumors when only one
deposit of nCaPCMHACDDP was found. When nCaPCMHACDDP was administered the goal was
to deposit the nanoparticles in two locations opposite one another, but for some tumors this was
not achieved. We believe the lack of distribution of nCaPCMHACDDP throughout the tumor
contributed to the lack of efficacy observed because drug exposure was limited to one side of the
tumor. Moving forward nCaPCMHACDDP could be given using intravenous (IV) administration
to aid in distribution of nCaPCMHACDDP throughout the tumor. IV administration will allow
nCaPCMHACDDP to passively target the tumor via the enhanced permeability and retention (EPR)
effect7,172–174 in addition to active targeting via CD44 expression in cancer cells.

Once
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nCaPCMHACDDP reaches the tumor, CD44 mediated uptake175 and an acidic tumor
microenvironment will enhance CDDP release locally.
Choice of animal model is essential to obtaining statistically significant, meaningful
results. Within this dissertation we studied mouse HNC via SCCVII cells in CH3/HeJ mice,
human HNC via FaDu cells in Nu/J mice and human TNBC via BT-474m cells in J:Nu mice.
SCCVII cells are very aggressive, which is well published63,128,176. This model was chosen
because of their aggressive phenotype, with the goal of overcoming the fast tumor growth with
local delivery of CDDP via nCaPDCDDP. We found that only local delivery of CDDP had a
significant effect at delaying tumor growth and this was only found when all animals were
treated when their tumor volume reached strictly within ±10% of one another, specifically 160
mm3 for the second efficacy study (Figure 2.19). Due to the aggressive nature of these tumors
only 20% of animals remained in the most effective treatment group, CDDP IT, at the 20 day
completion of the study. All other animals had to be euthanized due to a tumor diameter > 2 cm,
weight loss, or tumor necrosis, prior to day 20 following treatment. This model is too aggressive
and consequently we moved to the use of a human HNC model, which employed FaDu cells.
FaDu cells proved to be less aggressive, where animals treated with control treatments of saline
or nCaPCIT alone were able to survive for 16 to 27 days and all of the animals in the CDDP IT
treatment group survived 30 days. This model proved to develop tumors that when left untreated,
all grew within a close tumor volume range of one another, which limited variability within
treatment groups. Additionally, necrosis and rapid tumor growth (diameter > 2 cm 10 days
following treatment) was not an issue. In Chapter 4 of this dissertation, we aimed to target
human, CD44 expressing, therapy resistant TNBC. BT-474m cells proved to be an excellent
model for this in vitro but when these cells were inoculated in J:Nu mice their growth was highly
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variable.

This may be due to an insufficient number of cells injected, loss of aggressive

phenotype in vivo or an immune response in the J:Nu mice. We chose to use this cell type
because they uniquely represent a sub-set of transformed, triple negative breast cancer (TNBC)
cells which are CD44+/CD24-. This type of cancer cell has not previously been examined for in
vivo tumor take rate or anti-cancer efficacy using CDDP, but has excellent clinical relevance
towards more effective treatment of TNBC. It is likely that moving forward with this cell line
will require inoculating mice with a higher concentration of cells, where we injected 5 x 105 and
something more comparable to what was used for FaDu tumors would be more appropriate, 2 x
106 cells. This can be evaluated using an additional tumor take rate study. It is essential to
determine an appropriate animal model that will result in tumors that will grow beyond
inoculation volume, but are not too aggressive causing necrosis and tumor diameters above limits
set by Institutional Animal Care.
Overall, nCaPCMHACDDP shows great promise for the treatment of TNBC. CD44
expression is also common in HNC37,177–180, therefore revisiting the HNC model in vitro and in
vivo with the nCaPCMHACDDP formulation is of interest. A thorough maximum tolerable dose
study with a wider range of doses of nCaPCMHACDDP should be performed prior to a repeat
efficacy study. It is likely that a higher dose of nCaPCMHACDDP will be safe, as no animals lost
more than 5% of their weight at time of treatment due to the 7 mg/kg dose used in Chapter 4.
The cytotoxicity studies were very promising and thus we anticipated significant tumor growth
delay in vivo. With thorough characterization and optimization nCaPCMHACDDP has excellent
potential for localized treatment of CD44+ cancers, like TNBC and HNC.
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